



(19) Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) EP 0 722 936 A1

(12) **EUROPEAN PATENT APPLICATION**
published in accordance with Art. 158(3) EPC

(43) Date of publication:
24.07.1996 Bulletin 1996/30

(51) Int. Cl.⁶: C07D 237/30, C07D 237/32,
C07D 237/34, A61K 31/50

(21) Application number: 95927990.2

(86) International application number:
PCT/JP95/01575

(22) Date of filing: 08.08.1995

(87) International publication number:
WO 96/05176 (22.02.1996 Gazette 1996/09)

(84) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT
SE

- MIYAZAKI, Kazuki
Tsukuba-shi Ibaraki 305 (JP)
- MATSUKURA, Masayuki
Tsukuba-shi Ibaraki 300-26 (JP)
- SOUDA, Shigeru
Ushiku-shi Ibaraki 300-12 (JP)
- MIYAKE, Kazutoshi
Ushiku-shi Ibaraki 300-12 (JP)
- ISHIHARA, Hiroki
Tsukuba-shi Ibaraki 305 (JP)
- KODAMA, Kohtaro
Tsukuba-shi Ibaraki 305 (JP)
- ADACHI, Hideyuki
Inashiki-gun Ibaraki 300-03 (JP)

(30) Priority: 09.08.1994 JP 187128/94
20.12.1994 JP 316337/94

(71) Applicant: Eisai Co., Ltd.
Tokyo 112-88 (JP)

(72) Inventors:


- WATANABE, Nobuhisa
Tsukuba-shi Ibaraki 305 (JP)
- KABASAWA, Yasuhiro
Tukuba-shi Ibaraki 305 (JP)
- TAKASE, Yasutaka
Tsukuba-shi Ibaraki 305 (JP)
- OZAKI, Fumihiro
Ushiku-shi Ibaraki 300-12 (JP)
- ISHIBASHI, Keiji
Tsukuba-shi Ibaraki 305 (JP)

(74) Representative: Thiel, Christian, Dr. Dipl.-Chem.
et al
Schaeferstrasse 18
44623 Herne (DE)

(54) **FUSED PYRIDAZINE COMPOUND**

(57) A fused pyridazine compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof which exhibits an inhibitory activity against cyclic GMP phosphodiesterase (hereinafter referred to as "cGMP-PDE").

The compounds are useful as preventive and therapeutic agents for diseases for which a cGMP-PDE inhibiting action is efficacious, for example, ischemic heart diseases such as angina pectoris, myocardial infarct and chronic and acute cardiac failure, pulmonary hypertension, arteriosclerosis and bronchial asthma.



Description**Field of the Invention**

5 The present invention relates to a novel fused pyridazine compound. In particular, the present invention relates to a novel fused pyridazine compound which is useful as drug.

Description of Related Background Art

10 Recently, studies on compounds exhibiting inhibitory activity against cyclic GMP phosphodiesterase (hereinafter referred to as "cGMP-PDE") have proceeded and attempts have been made to apply such compounds to the prevention and treatment of circulatory failures such as hypertension, angina pectoris and myocardial infarct.

Known examples of the compound usable in the prevention and treatment of circulatory failures include quinazoline compounds disclosed in JP-A-29582/1975, 4H-3,1-benzoxazin-4-one compounds disclosed in WO 88/09790. 1H-
15 2,3,4,5-tetrahydroimidazo[2,1-b]quinazolin-2-one and 1,2,3,4,5,6-hexahydropyrimido[2,1-b]quinazolin-2-one disclosed in JP-A-86894/1973, nitrogenous heterocyclic compounds disclosed in WO 93/07124 and 4-aminoquinazoline derivatives disclosed in EP 579496.

However, most of the compounds described above are not on the market and many of them have problems of solubility, *in vivo* dynamics and toxicity which must be solved prior to the use as drugs.


20 Disclosure of the Invention

Under the above circumstances, the inventors of the present invention have started their studies for the purpose of finding a compound which exhibits an excellent cGMP-PDE inhibiting activity, has such a high water solubility as to be well absorbed into the living body, and is less toxic.

25 As a result of the studies, they have found that the above object can be attained by a fused pyridazine compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof. The present invention has been accomplished on the basis of this finding.

30

35




40

{wherein ring C represents a five- or six-membered ring which may contain a heteroatom;
n is an integer of 0 to 4;

45 R¹ represents a halogen atom, an optionally substituted lower alkyl group, optionally substituted lower alkoxy group, an optionally substituted cycloalkyl group, a nitro group, a cyano group, -NR²R³ (wherein R² and R³ represent each independently a hydrogen atom, an optionally substituted lower alkyl group, an acyl group, optionally substituted arylalkyl group or an optionally substituted heteroarylalkyl group, or alternatively R² and R³ together with the nitrogen atom to which they are bonded may form a ring which may be substituted), -O-R⁹ (wherein R⁹ represents a hydrogen atom, an optionally substituted lower alkyl group, an acyl group, an optionally substituted arylalkyl group or an optionally substituted heteroarylalkyl group), -S-R¹⁰ (wherein R¹⁰ represents a hydrogen atom, an optionally substituted lower alkyl group, an acyl group, an optionally substituted arylalkyl group or an optionally substituted heteroarylalkyl group),

55



(wherein R¹¹ represents a hydrogen atom, a lower alkyl group or an amino group; and m is an integer of 0 to 2), or an

optionally protected carboxyl group, with the proviso that when n is 2 to 4, R¹'s represent each independently a substituent selected from among those described above;

A represents a hydrogen atom, a halogen atom, -NR⁴R⁵ (wherein R⁴ and R⁵ represent each independently a hydrogen atom, an optionally substituted lower alkyl group, an acyl group, an optionally substituted arylalkyl group or an optionally substituted heteroarylalkyl group, or alternatively R⁴ and R⁵ together with the nitrogen atom to which they are bonded may form a ring which may be substituted), an optionally substituted aryl group, an optionally substituted heteroaryl group, an optionally substituted arylalkyl group or an optionally substituted heteroarylalkyl group;

X represents -NR⁶- (wherein R⁶ represents a hydrogen atom, an optionally substituted lower alkyl group, an optionally substituted arylalkyl group or an optionally substituted heteroarylalkyl group) or -N=;

Y represents -CO- or -CB= [wherein B represents a hydrogen atom, a halogen atom, -NR⁷R⁸ (wherein R⁷ and R⁸ represent each independently a hydrogen atom, an optionally substituted lower alkyl group, an acyl group, an optionally substituted arylalkyl group or an optionally substituted heteroarylalkyl group, or alternatively R⁷ and R⁸ together with the nitrogen atom to which they are bonded may form a ring which may be substituted), -O-R¹² (wherein R¹² represents a hydrogen atom, an optionally substituted lower alkyl group, an acyl group, an optionally substituted arylalkyl group or an optionally substituted heteroarylalkyl group), -S-R¹³ (wherein R¹³ represents a hydrogen atom, an optionally substituted lower alkyl group, an acyl group, an optionally substituted arylalkyl group or an optionally substituted heteroarylalkyl group), an optionally substituted aryl group, an optionally substituted heteroaryl group, an optionally substituted arylalkyl group or an optionally substituted heteroarylalkyl group]; and the symbol -----

represents a double bond or a single bond, with the proviso that the cases wherein C represents a benzene ring and n is 0) are excepted.)

In the above definition of the general formula (I), the lower alkyl group constituting the optionally substituted lower alkyl as defined with respect to R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹² and R¹³ may be a linear or branched lower alkyl group having 1 to 6 carbon atoms, and examples thereof include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 1-methylpropyl, tert-butyl, n-pentyl, 1-ethylpropyl, isoamyl and n-hexyl. The substituent constituting it includes a hydroxyl group, a nitro group, an amino group, a cyano group, acyl groups such as an acetyl group and a benzoyl group; lower alkoxy groups such as a methoxy group and an ethoxy group; halogen atoms such as a fluorine atom, a chlorine atom, a bromine atom and an iodine atom; and an optionally protected carboxyl group. One or more of these substituents may be bonded to one or more carbon atoms of the lower alkyl group.

The lower alkoxy group constituting the optionally substituted lower alkoxy group as defined with respect to R¹ may be one derived from the above lower alkyl group, and examples thereof include a methoxy group, an ethoxy group and a propoxy group.

The substituent constituting it includes a hydroxyl group, a nitro group, an amino group, a cyano group, acyl groups such as an acetyl group and a benzoyl group; lower alkoxy groups such as a methoxy group and an ethoxy group; halogen atoms such as a fluorine atom, a chlorine atom, a bromine atom and an iodine atom; and an optionally protected carboxyl group. One or more of these substituents may be bonded to one or more carbon atoms of the lower alkoxy group.

The cycloalkyl group constituting the optionally substituted cycloalkyl group as defined with respect to R¹ may be one having 3 to 8 carbon atoms, while the substituent constituting it includes a hydroxyl group, a nitro group, an amino group, a cyano group, an acyl groups such as an acetyl group and a benzoyl group; lower alkoxy groups such as a methoxy group and an ethoxy group; halogen atoms such as a fluorine atom, a chlorine atom, a bromine atom and an iodine atom; and an optionally protected carboxyl group. One or more of these substituents may be bonded to one or more carbon atoms of the cycloalkyl group.

The acyl group as defined with respect to R², R³, R⁴, R⁵, R⁷, R⁸, R⁹, R¹⁰, R¹² and R¹³ may be one derived from an aliphatic, aromatic or acyl group derived from heterocyclic ring, and examples thereof include lower alkanoyl groups such as a formyl group, an acetyl group, a propionyl group, a butyryl group, a valeryl group, an isovaleryl group and a pivaloyl group; aroyl groups such as a benzoyl group, a toluoyl group and a naphthoyl group; and heteroaroyl groups such as a furoyl group, a nicotinoyl group and an isonicotinoyl group. In short, the group may be one derived from any carboxylic acid. Among these, a formyl group, an acetyl group and a benzoyl group are preferable.

The aryl group constituting the optionally substituted aryl as defined with respect to A and B may be one derived from an aromatic ring, and examples thereof include phenyl, 1-naphthyl, 2-naphthyl and anthracenyl. The substituent constituting it includes a hydroxyl group, a nitro group, an amino group, a cyano group, acyl groups such as an acetyl group and a benzoyl group; a lower alkoxy group such as a methoxy group and an ethoxy group; halogen atoms such as a fluorine atom, a chlorine atom, a bromine atom and an iodine atom; and an optionally protected carboxyl group.

The heteroaryl group constituting the optionally substituted heteroarylalkyl group as defined with respect to A and B may be a mono- or poly-cyclic group having one or more heteroatoms selected from among nitrogen, sulfur and oxygen atom. Examples thereof include pyridyl, pyrrolyl, imidazolyl, pyrazolyl, pyrazyl, pyrimidyl, pyradazyl, thienyl, pyranyl, isothiazolyl, isoxazolyl, furazanyl, benzothienyl, furyl, indolyl, indolizinyl, isoindolyl, benzothiazolyl, benzimidazolyl and quinazolyl. The substituent constituting it includes a hydroxyl group, a nitro group, an amino group, a cyano group, acyl groups such as an acetyl group and a benzoyl group; lower alkoxy groups such as a methoxy group and an ethoxy

group; halogen atoms such as a fluorine group, a chlorine group, a bromine group and an iodine group; and an optionally protected carboxyl group.

As defined above, R⁷ and R⁸ together with the nitrogen atom to which they are bonded may form a ring which may be substituted, and examples of the ring include piperidinyl, pyrrolidinyl and piperazinyl. The substituent for the ring includes a hydroxyl group, an optionally substituted amino group, an aminoalkyl group, a nitro group, a nitroalkyl group, a lower alkoxy group, a lower alkoxyalkyl group, a hydroxyalkyl group, an optionally protected carboxyl group and an optionally protected carboxyalkyl group, among which a hydroxyl group, a hydroxymethyl group, a hydroxyethyl group, a carboxymethyl group and a carboxyethyl group are preferable.

The aryl group constituting the optionally substituted arylalkyl group as defined with respect to R², R³, R⁴, R⁵, R⁶,

R⁷, R⁸, R⁹, R¹⁰, R¹², R¹³ and Y may be one derived from an aromatic ring, and examples thereof include phenyl, 1-naphthyl, 2-naphthyl and anthracenyl. The group corresponding to the "alkyl" moiety constituting it may be one derived from the above lower alkyl group. The substituent constituting it includes a hydroxyl group, a nitro group, an amino group, a cyano group, acyl groups such as an acetyl group and a benzoyl group; lower alkoxy groups such as a methoxy group and an ethoxy group; halogen atoms such as a fluorine atom, a chlorine group, a bromine atom and an iodine group; and an optionally protected carboxyl group.

The heteroaryl group constituting the optionally substituted heteroaryalkyl as defined with respect to R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹², R¹³ and Y may be a mono- or poly-cyclic group having one or more heteroatoms selected from among a nitrogen atom, a sulfur atom and an oxygen atom, and examples thereof include pyridyl, pyrrolyl, imidazolyl, pyrazolyl, pyrazyl, pyrimidyl, pyridazyl, thieryl, pyranyl, isothiazolyl, isoxazolyl, furazanyl, benzothienyl, furyl, indolyl, indolizinyl, isoindolyl, benzothiazolyl, benzoimidazolyl and quinazolyl. The group corresponding to the "alkyl" moiety constituting it may be one derived from the above lower alkyl group. The substituent constituting it includes a hydroxyl group, a nitro group, an amino group, a cyano group, acyl groups such as an acetyl group and a benzoyl group; lower alkoxy groups such as a methoxy group and an ethoxy group; halogen atoms such as a fluorine atom, a chlorine atom, a bromine atom and an iodine group; and an optionally protected carboxyl group.


The halogen atom as defined with respect to R¹, R¹², R¹³ and R¹⁴ includes a fluorine atom, a chlorine atom, a bromine atom and an iodine atom.

The pharmacologically acceptable salt according to the present invention includes inorganic acid salts such as hydrochloride, sulfate, hydrobromide and phosphate; and organic acid salts such as formate, acetate, trifluoroacetate, maleate, fumarate, tartrate, methanesulfonate, benzenesulfonate and toluenesulfonate.

Although several compounds according to the present invention form hydrates, it is needless to say that the hydrates fall within the scope of the present invention.


Among the compounds of the present invention, fused pyridazine compounds represented by the following general formula (II) and pharmacologically acceptable salts thereof are preferable:

35



(wherein R¹ represents a hydrogen atom, a halogen atom, an optionally substituted lower alkyl group, an optionally substituted lower alkoxy group, an optionally substituted cycloalkyl group, a nitro group, a cyano group, -NR²R³ (wherein R² and R³ represent each independently a hydrogen atom, an optionally substituted lower alkyl group, an acyl group, an optionally substituted arylalkyl group or an optionally substituted heteroaryalkyl group, or alternatively R² and R³ together with the nitrogen atom to which they are bonded may form a ring which may be substituted), -O-R⁹ (wherein R⁹ represents a hydrogen group, an optionally substituted lower alkyl group, an acyl group, an optionally substituted arylalkyl group or an optionally substituted heteroaryalkyl group), -S-R¹⁰ (wherein R¹⁰ represents a hydrogen atom, an optionally substituted lower alkyl group, an acyl group, an optionally substituted arylalkyl group or an optionally substituted heteroaryalkyl group),

55



(wherein R¹¹ represents a hydrogen atom, a lower alkyl group or an amino group; and m is an integer of 0 to 2), or an optionally protected carboxyl, with the proviso that when n is 2 to 4, R¹'s represent each independently a substituent selected from among those described above;

5 A represents a hydrogen atom, a halogen atom, -NR⁴R⁵ (wherein R⁴ and R⁵ represent each independently a hydrogen atom, an optionally substituted lower alkyl atom, an acyl group, an optionally substituted arylalkyl group or an optionally substituted heteroarylalkyl group, or alternatively R⁴ and R⁵ together with the nitrogen atom to which they are bonded may form a ring which may be substituted), an optionally substituted aryl group, an optionally substituted heteroaryl group, an optionally substituted arylalkyl group or an optionally substituted heteroarylalkyl group;


10 X represents -NR⁶- (wherein R⁶ represents a hydrogen atom, an optionally substituted lower alkyl group, an optionally substituted arylalkyl group or an optionally substituted heteroaryl group) or -N=;

15 Y represents -CO- or -CB= (wherein B represents a hydrogen group, a halogen atom, -NR⁷R⁸ (wherein R⁷ and R⁸ represent each independently a hydrogen atom, an optionally substituted lower alkyl group, an acyl group, an optionally substituted arylalkyl group or an optionally substituted heteroarylalkyl group, or alternatively R⁷ and R⁸ together with the nitrogen atom to which they are bonded may form a ring which may be substituted), -O-R¹² (wherein R¹² represents a hydrogen atom, an optionally substituted lower alkyl group, an acyl group, an optionally substituted arylalkyl group or an optionally substituted heteroarylalkyl group), -S-R¹³ (wherein R¹³ represents a hydrogen atom, an optionally substituted lower alkyl group, an acyl group, an optionally substituted arylalkyl group or an optionally substituted heteroarylalkyl group), an optionally substituted aryl group, an optionally substituted heteroaryl group, an optionally substituted arylalkyl group or an optionally substituted heteroarylalkyl group); and the symbol -----

20 represents a double bond or a single bond, with the proviso that the cases wherein ring C represents a benzene ring and n is 0 are excepted.

Among the above preferable compounds, fused pyridazine compounds represented by the following general formula (III) and pharmacologically acceptable salts thereof are desirable:

25




30

35

[wherein R^{1a} represents a halogen atom, an optionally substituted lower alkyl group, an optionally substituted lower alkoxy group, an optionally substituted cycloalkyl group, a nitro group, a cyano group or -NR²R³ (wherein R² and R³ represent each independently a hydrogen atom, an optionally substituted lower alkyl group, an acyl group, an optionally substituted arylalkyl group or an optionally substituted heteroarylalkyl group, or alternatively R² and R³ together with the nitrogen atom to which they are bonded may form a ring which may be substituted);

40 R¹ represents a hydrogen atom, a halogen atom, an optionally substituted lower alkyl group, an optionally substituted lower alkoxy group, an optionally substituted cycloalkyl group, a nitro group, a cyano group, -NR²R³ (wherein R² and R³ represent each independently a hydrogen atom, an optionally substituted lower alkyl group, an acyl group, an optionally substituted arylalkyl group or an optionally substituted heteroarylalkyl group, or alternatively R² and R³ together with the nitrogen atom to which they are bonded may form a ring which may be substituted), -O-R⁹ (wherein R⁹ represents a hydrogen atom, an optionally substituted lower alkyl group, an acyl group, an optionally substituted arylalkyl group or an optionally substituted heteroarylalkyl group), -S-R¹⁰ (wherein R¹⁰ represents a hydrogen atom, an optionally substituted lower alkyl group, an acyl group, an optionally substituted arylalkyl group or an optionally substituted heteroarylalkyl group),

50




55

(wherein R¹¹ represents a hydrogen atom, a lower alkyl group or an amino group; and m is an integer of 0 to 2), or an optionally protected carboxyl group, with the proviso that when n is 2 to 4, R¹'s represent each independently a substituent selected from among those described above;

A represents a hydrogen atom, a halogen atom, -NR⁴R⁵ (wherein R⁴ and R⁵ represent each independently a hydrogen atom, an optionally substituted lower alkyl group, an acyl group, an optionally substituted arylalkyl group or an optionally substituted heteroarylalkyl group, or alternatively R⁴ and R⁵ together with the nitrogen atom to which they are bonded may form a ring which may be substituted), an optionally substituted aryl group, an optionally substituted heteroaryl group, an optionally substituted arylalkyl group or an optionally substituted heteroarylalkyl group; and

B represents a hydrogen atom, a halogen atom, -NR⁷R⁸ (wherein R⁷ and R⁸ represent each independently a hydrogen atom, an optionally substituted lower alkyl group, an acyl group, an optionally substituted arylalkyl group or an optionally substituted heteroarylalkyl group, or alternatively R⁷ and R⁸ together with the nitrogen atom to which they are bonded may form a ring which may be substituted), -O-R¹² (wherein R¹² represents a hydrogen atom, an optionally substituted lower alkyl group, an acyl group, an optionally substituted arylalkyl group or an optionally substituted heteroarylalkyl group), -S-R¹³ (wherein R¹³ represents a hydrogen, an optionally substituted lower alkyl group, an acyl group, an optionally substituted arylalkyl group or an optionally substituted heteroarylalkyl group), an optionally substituted aryl group, an optionally substituted heteroaryl group, an optionally substituted arylalkyl group or an optionally substituted heteroarylalkyl group].

Further, fused pyridazine compounds represented by the following general formula (V) and pharmacologically acceptable salts thereof are more desirable:




(wherein R^{1a} represents a halogen atom, an optionally substituted lower alkyl group, an optionally substituted lower alkoxy group, an optionally substituted cycloalkyl group, a nitro group, a cyano group or -NR²R³ (wherein R² and R³ represent each independently a hydrogen atom, an optionally substituted lower alkyl group, an acyl group, an optionally substituted arylalkyl group or an optionally substituted heteroarylalkyl group, or alternatively R² and R³ together with the nitrogen atom to which they are bonded may form a ring which may be substituted);

B represents a hydrogen atom, a halogen atom, -NR⁷R⁸ (wherein R⁷ and R⁸ represent each independently a hydrogen atom, an optionally substituted lower alkyl group, an acyl group, an optionally substituted arylalkyl group or an optionally substituted heteroarylalkyl group, or alternatively R⁷ and R⁸ together with the nitrogen atom to which they are bonded may form a ring which may be substituted), -O-R¹² (wherein R¹² represents a hydrogen atom, an optionally substituted lower alkyl group, an acyl group, an optionally substituted arylalkyl group or an optionally substituted heteroarylalkyl group), -S-R¹³ (wherein R¹³ represents a hydrogen atom, an optionally substituted lower alkyl group, an acyl group, an optionally substituted arylalkyl group or an optionally substituted heteroarylalkyl group), an optionally substituted aryl group, an optionally substituted heteroaryl group, an optionally substituted arylalkyl group or an optionally substituted heteroarylalkyl group; and

R¹², R¹³ and R¹⁴ represent each independently a hydrogen atom, a halogen atom, an optionally substituted lower alkyl group or an optionally substituted lower alkoxy group, or alternatively two of R¹², R¹³ and R¹⁴ which are bonded to the carbon atoms adjacent to each other may be united to form methylenedioxy or ethylenedioxy).

Furthermore, compounds represented by the following general formula (V') are most desirable:




(wherein R^{1a} represents a halogen atom, a nitro group or a cyano group, preferably a cyano group; B desirably represents -NR⁷R⁸ (wherein R⁷ and R⁸ represent each independently a hydrogen atom, an optionally substituted lower alkyl group, an acyl group, an optionally substituted arylalkyl group or an optionally substituted heteroarylalkyl group, or alternatively R⁷ and R⁸ together with the nitrogen atom to which they are bonded may form a ring which may be substituted), more desirably -NR⁷R⁸ (wherein R⁷ and R⁸ together with the nitrogen atom to which they are bonded form a ring which is preferably substituted with a hydroxyl group, a carboxyl group, a hydroxylalkyl group, a carboxyalkyl group or the like, still preferably at the position 4. It is most desirable that the substituent is a hydroxyl group or hydroxylalkyl group.

The compounds of the present invention can be readily prepared by known processes or combinations of known processes. Several main processes for the preparation of the compounds of the present invention will now be described, though it is needless to say that the compounds of the present invention are not limited to those prepared by these processes.

Preparation process 1


15 A compound represented by the general formula (I) wherein A and B are each a halogen atom can be prepared by the following process:



(wherein A' and B' represent each independently a halogen atom; and R¹ and n are each as defined above) Specifically, the above compound can be prepared by halogenating a corresponding 1,4-phthalazinedione derivative. This halogenation can be conducted in a conventional manner. Examples of the chlorinating agent usable in this case include phosphorus pentachloride, phosphorus oxychloride and mixture of both. Although the halogenation can be conducted without any solvent, any solvent inert to the halogenation may be used. In some cases, the use of a tertiary amine such as diisopropylethylamine or N,N-dimethylformamide gives better results. The reaction temperature preferably ranges from about room temperature to about 150°C.

Preparation process 2


40 A compound represented by the general formula (I) wherein ring C represents a benzene ring; A and B represent each independently a halogen atom; R¹ represents a cyano group; and n is 1 can be prepared also by the following process:



5

10

15



(VIII')

(wherein A' and B' are each as defined above)

20

(1st step)

In this step, the amino group of 4-aminophthalimide is converted into a cyano group. This conversion is preferably conducted by the Sandmeyer reaction, though it may be conducted by any conventional process. According to the 25 Sandmeyer reaction, the conversion is conducted by converting 4-aminophthalimide into a diazonium salt in a conventional manner and thereafter reacting the diazonium salt with a nucleophilic reagent such as copper salt to replace the diazonium group by a cyano group. Although commercially available copper cyanide may be used in this reaction, better results can be attained by the use of the copper cyanide prepared from potassium cyanide and cuprous chloride just before use.

30

(2nd step)

In this step, the phthalimide derivative prepared in the 1st step is converted into a corresponding 1,4-phthalazinedione. This conversion can be conducted according to the process described in Castle: "HETEROCYCLIC COM- 35 POUNDS". Vol.27.

(3rd step)


In this step, the 1,4-phthalazinedione prepared in the above 2nd step is prepared according to Preparation process 40 1.

Preparation process 3

A compound represented by the general formula (I) wherein ring C represents a benzene ring; A and B represent 45 each independently a halogen atom; R¹ represents a cyano group; and n is 1 can be prepared also by the following process:

50

55



(wherein A' and B' are each as defined above)

30

In this step, 4-carbamoylphthalimide is prepared by reacting trimellitoyl chloride with ammonia and dehydrating the obtained product. Specifically, this reaction is conducted by reacting trimellitoyl chloride with aqueous ammonia either without any solvent or in a state dissolved in a solvent at a temperature ranging from about -15°C to room temperature. The solvent to be used in this case is preferably acetone, dichloromethane, chloroform or ethyl acetate, though any organic solvent inert to the reaction may be used. The resulting reaction mixture is treated with an acid to give a mixture comprising 2,4-dicarbamoylbenzoic acid and 2,5-dicarbamoylbenzoic acid. This mixture is further treated in the absence or presence of a solvent for 0.5 to 24 hours to give the objective compound. This treatment is conducted at room temperature to about 200°C. The solvent to be used in this treatment is preferably N-methyl-2-pyrrolidinone, though any solvent inert to the reaction may be used.

(2nd step)

45 In this step, the phthalimide derivative prepared in the above 1st step is converted into a phthalazinedione in a conventional manner.


This conversion can be conducted by a conventional process such as reaction with hydrazine hydrate or the like. The reaction temperature is preferably 0°C to room temperature.

50 (3rd step)

In this step, the 6-carbamoyl-2,3-dihydro-1,4-phthalazinedione prepared in the 2nd step is converted into 6-cyano-1,4-dichlorophthalazine through dehydration and chlorination. The reagent useable in this case includes phosphorus oxychloride, thionyl chloride, phosphorus pentachloride and mixtures of two or more of them. The reaction temperature may range from room temperature to the boiling point of the reagent and the reaction time is about 0.5 to 36 hours. In some cases, better results can be attained by the addition of N,N-dimethylformamide or a tertiary amine such as diisopropylethylamine.

Preparation process 4

5 A compound represented by the formula (I) wherein A represents $-NR^2R^3$ (wherein R^2 and R^3 represent each independently a hydrogen atom, an optionally substituted lower alkyl group, an acyl group, an optionally substituted arylalkyl group or an optionally substituted heteroarylalkyl group, or alternatively R^2 and R^3 together with the nitrogen atom to which they are bonded may form a ring which may be substituted) and B represents a halogen atom can be prepared by the following process:



(wherein A' represents a halogen atom; and R¹, R², R³, X and Y are each as defined above).

Specifically, the above compound is prepared through the conventional substitution reaction. The solvent to be used in the reaction may be any organic one inert to the reaction, and preferable examples of the solvent include alcohols such as isopropyl alcohol; ethers such as tetrahydrofuran and 1,4-dioxane; dimethylformamide, dimethylacetamide and N-methyl-2-pyrrolidinone.


25 The reaction temperature may preferably range from about room temperature to the refluxing temperature of the solvent.

Better results can be attained by the addition of a salt such as potassium carbonate, sodium carbonate or barium carbonate, or a tertiary amine such as diisopropylethylamine or DBU. In particular, the addition of a tertiary amine such as diisopropylethylamine or DBU can give the best results.

After the completion of the reaction, the reaction mixture is post-treated in a conventional manner and is freed from undesirable isomers by recrystallization or treatment with a column to give an objective compound.

Preparation process 5

35 A compound represented by the general formula (I) can be prepared also by the following process:




50 (wherein R¹, A, B, A', B', X and n are each as defined above)

According to this process, the objective compound is prepared from the halophthalazine derivative prepared by Preparation process 4 or the like through conventional replacement. The solvent to be used in this case is preferably N-methyl-2-pyrrolidinone, though any solvent inert to the reaction may be used. The reactant B-H is used in excess based on the starting halophthalazine derivative. In some cases, better results can be attained by the addition of an organic base such as diisopropylethylamine, a salt such as potassium carbonate, sodium carbonate or sodium hydrogencarbonate, or an acid such as p-toluenesulfonic acid. Further, still better results can be attained by using hydrochloride of the compound B-H without the above additive.

The reaction temperature may be from about room temperature to the boiling point of the solvent, preferably 100°C or above.

Preparation process 6

A compound represented by the general formula (I) wherein Y is -CO- can be prepared by the following process:



(wherein R¹, A, B', X and n are each as defined above).

According to this process, the objective compound is prepared by hydrolyzing a corresponding halophthalazine derivative in a conventional manner. Specifically, the compound can be prepared by heating the corresponding halophthalazine derivative in an acidic or alkaline solution. In some case, better results can be attained when the halophthalazine derivative is stirred under heating at 100 to 200°C in an organic solvent such as N-methyl-2-pyrrolidinone in the presence of acetic acid for about 0.5 to 12 hours.

25 Pharmacological Experimental Examples will now be described to illustrate the effects of the present invention.

Pharmacological Experimental Example

Experimental Example 1

Inhibitory activity against cGMP-PDE prepared from swine lung

1. Experimental method

35 The enzyme activity of the cGMP-PDE prepared from swine lung was determined according to the method of Thompson et al. This determination was conducted in the presence of 1mM EGTA by the use of 1mM cGMP as substrate. Each compound according to the present invention was dissolved in DMSO and thereafter added to the reaction system to determine the inhibitory activity of the compound. The final concentration of DMSO in the reaction solution was controlled to 5% or below.

40 The preparation of cGMP-PDE was conducted as follows.

Swine lung was minced, followed by the addition of five times (by volume) as much buffer A (comprising Tris/HCl (20 mM), Mg acetate (2 mM), 2-mercaptoethanol (10 mM), EGTA (0.1 mM) and PMSF (0.2 mM) and adjusted to pH 7.4). The resulting mixture was homogenized and centrifuged at 1000 × g for 5 minutes. Ammonium sulfate was added to the obtained supernatant and the resulting mixture was centrifuged at 20000 × g for 45 minutes to collect a fraction precipitating between 30 and 40% saturation with ammonium sulfate. This fraction was dialyzed against buffer A and passed through a column of DEAE-Toyopearl 650S (a product of Tosoh, Tokyo, Japan). The column was washed with buffer A and subjected to gradient elution with 0.05 to 0.2 M NaCl/buffer A to collect a cGMP-PDE fraction.

This cGMP-PDE fraction was passed through Blue-Sepharose CL-6B (a product of Pharmacia, Uppsala, Sweden). The resulting column was washed with buffer A containing cAMP (10 mM) and NaCl (0.5 M) and eluted with buffer A containing cGMP (10 mM) and NaCl (0.5 M). The obtained fraction was dialyzed, concentrated and stored.

2. Experimental results

The cGMP-PDE inhibitory activities of the compounds of the present invention as determined by the above method
55 are given in Table 1.

	Ex. No.	cGMP-PDE inhibitory activity IC50(nM)	PAP lowering activity
5	1	1.7	≥3
10	4	0.18	—
15	6	0.015	10
20	7	1.2	1
25	8	0.03	10
30	9	0.70	10
35	10	0.01	10
40	11	0.11	—
45	17	≤0.01	—
50	19	0.53	3-10
	20	0.12	0.3-1
	25	1.41	3
	26	4.0	1
	31	3.74	1
	32	4.4	1
	36	1.9	≥1
	37	1.8	≤0.33
	43	0.37	1
	44	2.1	≤0.33
	49	1.88	1
	51	0.052	—
	52	0.10	10
	56	12.6	≥1
	53	0.23	10
	55	4.59	≥1
	60	20.4	1
	67	0.32	0.33

Experimental Example 2

Pulmonary arterial pressure lowering activity on anesthetized thoracotomized dog by intravenous administration

5 1. Experimental method

Male and female hybrid dogs having a weight of about 10 kg were operated under enflurane anesthesia with N₂O/O₂ as carrier. Each dog was thoracotomized in the left fourth intercostal space and a pressure transducer (MPC-500 mfd. by Miller) was inserted into the pulmonary artery to determine the pulmonary arterial pressure (PAP). This 10 experiment was conducted with the mean PAP (mPAP) increased by about 10 mmHg by lowering the pressure of oxygen fed by about 40% of the normal one. Each compound according to the present invention was dissolved in Polyethylene glycol 400 (a product of Wako Pure Chemical Industries, Ltd.) in a concentration of 1 mg/ml and, if necessary, further diluted with Polyethylene glycol 400. The resulting solution was intravenously administered to the dog through a 15 polyethylene catheter indwelling in the femoral vein.

15 2. Experimental results

The PAP lowering activities of the compounds of the present invention as determined by the above method are given in Table 1 in terms of relative ratios to the activity of sodium 1-[chloro-4-(3,4-methylenedioxybenzyl)aminoquinazolin-2-yl]piperidine-4-carboxylate.

Experimental Example 3

In vitro platelet aggregation inhibiting activity

25 1. Experimental method

Blood specimens (100ml) were collected from the forearm veins of normal male volunteers (age: 30 to 40 years, weight: 60 to 75 kg) who had not taken any drug for at least one week therebefore. In order to prevent blood coagulation, 30 a 3.8% sodium citrate solution (Citral, a product of Yamanouchi Pharmaceutical Co., Ltd.) was added to the blood in an amount of one tenth of the blood volume. The resulting blood was centrifuged at room temperature (22-25°C) at 700 rpm for 10 minutes to recover a supernatant as platelet rich plasma (PRP). A blood anticoagulant solution (a product of Terumo Corporation) was added to the PRP in a final concentration of 15 v/v%. The resulting mixture was centrifuged at room temperature at 3000 rpm for 10 minutes to give a platelet pellet. This platelet pellet was suspended in physiological saline solution containing 0.1% of EDTA and the resulting suspension was centrifuged again to give another 35 platelet pellet. This pellet was suspended in Ca²⁺-free Tyrode's solution in a final concentration of about 40 × 10⁷/ml.

The platelet aggregation was determined according to the turbidimetric method of Born et al. with an aggregometer (PAM-8C mfd. by Mebanix). Each compound according to the present invention was dissolved in DMSO in a concentration of 50 mM, followed by serial dilution with Ca²⁺-free Tyrode's solution. The Ca²⁺-free Tyrode's solution was used 40 also as control.

A mixture comprising 25 ml of each of the dilutions of the compound of the present invention prepared above and 200 ml of the washed platelet prepared above was incubated, followed by the addition of 25 ml of a platelet coagulant. The resulting mixture was observed for aggregation. The platelet coagulant used was 3 mg/ml collagen (a product of Hormon-Chemie), 0.3 mM U46619 (a product of Cayman Chemical) or 0.04 U/ml thrombin (a product of Sigma).

45 The inhibitory activities of the compounds of the present invention were represented in terms of inhibitory ratios based on the aggregation intensity of control (the area of turbidity chart of the aggregometer).

2. Experimental results

50 The platelet aggregation inhibiting activities of the compounds of the present invention as determined by the above method are given in Table 2 in terms of 50% aggregation inhibitory concentrations (mM).

		Coagulant		
	Ex. No.	collagen	U46619	thrombin
5	4	11		5.6
10	18 (dihydrochloride-free)	20		21
	32	28		
15	43 (hydrochloride)	61	63	80
20	56	55	37	61

It can be understood from the results of the above pharmacological experiments that the compounds of the present invention exhibit cGMP-PDE inhibitory activity, platelet aggregation inhibiting activity and pulmonary arterial pressure lowering activity. Accordingly, the compounds of the present invention are useful as preventive and therapeutic agents for diseases for which cGMP-PDE inhibiting action, platelet aggregation inhibiting action or pulmonary arterial pressure lowering action is efficacious. Specific examples of such diseases include ischemic heart diseases such as angina pectoris, myocardial infarct and chronic and acute heart failures; pulmonary hypertension accompanied by pulmonary heart and that not accompanied thereby; thrombosis caused by trauma of vascular wall, arterial sclerosis, vasculitis and so forth; hypertension caused by arterial sclerosis and others; brain circulatory disturbances such as peripheral circulation failure and cerebral infarction; cerebral malfunction; and allergic diseases such as bronchial asthma, atopic dermatitis and allergic rhinitis.

The compounds of the present invention have higher water solubilities than those of the compounds of the prior art having similar activities and structures. Therefore, they are excellent in the migration into the living body in oral administration, which is an advantage of the compounds of the present invention.

Further, the compounds of the present invention are less toxic and highly safe, thus being extremely useful as drugs.

The compound of the present invention may be orally or parenterally administered as a therapeutic or preventive agent for the above diseases. Although the dose thereof is not particularly limited but varies depending upon the symptom, age, sex and drug sensitivity of patient; the method, timing and interval of administration; the properties and kind of preparation; the kind of active ingredient and so forth, the dose per adult a day is preferably about 0.1 to 1000 mg, which may be administered in one to several portions.

The compounds of the present invention can be converted into pharmaceutical preparations by the use of conventional carriers according to conventional processes.

More precisely, a solid preparation for oral administration according to the present invention is prepared by adding a filler and, if necessary, a binder, disintegrator, lubricant, color, corrigent and/or antioxidant to an active ingredient and shaping the obtained mixture into a tablet, coated tablet, granule, powder or capsule.

Examples of the filler include lactose, corn starch, sucrose, glucose, sorbitol, crystalline cellulose and silicon dioxide.

Examples of the binder include polyvinyl alcohol, polyvinyl ether, ethylcellulose, methylcellulose, acacia, tragacanth, gelatin, shellac, hydroxypropylcellulose, hydroxypropylmethylcellulose, calcium citrate, dextrin and pectin; and examples of the lubricant include magnesium stearate, talc, polyethylene glycol, silica and hardened vegetable oils.

Examples of the color include those authorized as pharmaceutical additives. Those of the corrigent include cocoa powder, menthol, aromatic powder, mentha oil, borneol and powdered cinnamon bark; and those of the antioxidant include those authorized as pharmaceutical additives such as ascorbic acid and α -tocopherol. Of course, the tablet and granule may be suitably coated with sugar, gelatin or the like, if necessary.

On the other hand, an injection according to the present invention is prepared by adding a pH modifier, buffer, suspending agent, solubilizing agent, stabilizer, tonicity agent, antioxidant and/or preservative to an active ingredient and formulating the mixture into an injection for intravenous, subcutaneous or intramuscular administration by a conventional process. If necessary, the injection may be freeze-dried.

Examples of the suspending agent include methylcellulose, Polysorbate 80, hydroxyethylcellulose, acacia, tragacanth powder, carboxymethylcellulose sodium and polyoxyethylene sorbitan monolaurate.

Further, examples of the solubilizing agent include polyoxyethylene hardened castor oil, Polysorbate 80, nicotinamide and polyoxyethylene sorbitan monolaurate.


Furthermore, examples of the stabilizer include sodium sulfite, sodium metasulfite and ether; and those of the preservative include methyl p-hydroxybenzoate, ethyl p-hydroxybenzoate, sorbic acid, phenol, cresol and chlorocresol.

Example

Examples will now be described to facilitate the understanding of the present invention, though it is needless to say that the present invention is not limited to them. These Examples are preceded by Preparative Examples for starting compounds. For the sake of convenience, some compounds of the present invention are described as Preparative Examples, which does not limit the present invention.

Preparative Example 1**10 4-Cyanophthalimide**

15



20

4-Aminophthalimide (40.0 g) was suspended in 300 ml of water, followed by the addition of 57 ml of concentrated hydrochloric acid. The obtained suspension was stirred under cooling with ice. A solution of 20.6 g of sodium nitrite in 25 69 ml of water was dropped into the above suspension at a bulk temperature of 5°C or below.

The obtained mixture was cooled to -20°C, followed by the addition of 300 ml of toluene. The resulting mixture was adjusted to pH7 with sodium hydrogencarbonate under vigorous stirring to form a diazonium salt.

Separately, a solution of 105.7 g of potassium cyanide in 206 ml of water was dropped into a suspension of 63.4 g of cuprous chloride in 250 ml of water, while the suspension was vigorously stirred under cooling with ice. The obtained 30 mixture was further stirred under cooling with ice for one hour, followed by the addition of 500 ml of ethyl acetate. The diazonium salt prepared above was added into the resulting mixture in several portions and the obtained mixture was stirred under cooling with ice for one hour.

The resulting mixture was filtered through Celite to remove insolubles and the Celite was washed with an ethyl acetate/tetrahydrofuran mixture. The filtrates were together left standing to cause liquid-liquid separation. The organic 35 phase was washed with a saturated aqueous solution of sodium hydrogencarbonate, dilute hydrochloric acid and a saturated aqueous solution of common salt, dried over anhydrous magnesium sulfate and freed from the solvent by vacuum distillation. The title compound (41 g) was obtained as a reddish-brown solid.


M.p.: 237.0-238.0°C

MASS: 173 (MH⁺)

40 ¹H-NMR (400 MHz, DMSO-d₆) δ: 8.00(1H, dd, J=7.5, 1.0Hz), 8.29(1H, dd, J=7.5, 1.5Hz), 8.36(1H, dd, J=1.5, 1.0Hz), 11.73(1H, s)

Preparative Example 2**45 6-Cyano-2,3-dihydro-1,4-phthalazinedione**

50



55

4-Cyanophthalimide (80 g) was suspended in 1000 ml of ethanol, followed by the addition of 25 ml of hydrazine monohydrate. The obtained mixture was stirred at room temperature for 5 hours.


The resulting mixture was concentrated in a vacuum to about one-half its original volume, followed by the addition of 1000 ml of water. The obtained mixture was acidified with dilute hydrochloric acid to precipitate crystals, which were recovered by filtration to give 71 g of the title compound as a brown powder.

1H-NMR (400 MHz, DMSO-d₆) δ: 8.19(1H, brs), 8.27(1H, dd, J=8.0, 1.0Hz), 8.48(1H, brs), 11.39(2H, brs)

Preparative Example 3

10 6-Cyano-1,4-dichlorophthalazine

15



20

25 6-Cyano-2,3-dihydro-1,4-phthalazinedione (69 g) was suspended in 400 ml of phosphorus oxychloride, followed by the addition of 75 ml of diisopropylethylamine. The obtained mixture was heated under reflux for 40 minutes.

Excess phosphorus oxychloride was distilled away in a vacuum and the residue was dissolved in methylene chloride. The obtained solution was poured onto ice/water. The resulting mixture was filtered through Celite to remove insolubles and the Celite was washed with methylene chloride. The filtrates were together extracted with methylene chloride and the organic phase was washed with a saturated aqueous solution of sodium hydrogencarbonate, dilute hydrochloric acid and a saturated aqueous solution of common salt, dried over anhydrous magnesium sulfate and filtered through silica gel. The filtrate was distilled in a vacuum to remove the solvent. The title compound (66 g) was obtained as a pale yellowish-orange solid.


30 1H-NMR (400 MHz, CDCl₃) δ: 8.24(1H, dd, J=8.5, 1.5Hz), 8.47(1H, dd, J=8.5, 1.0Hz), 8.68(1H, dd, J=1.5, 1.0Hz)

35

Preparative Example 4

40 4-Carbamoylphthalimide

45



50

A solution of 21.1 g (0.10 mol) of trimellitoyl chloride in 25 ml of acetone was dropped into 200 ml of 29% aqueous ammonia, while the aqueous ammonia was stirred under cooling with ice. The resulting mixture was as such stirred for one hour, deaerated in a vacuum and acidified with concentrated hydrochloric acid under cooling with ice. The crystals thus precipitated were recovered by filtration, washed with water and dried with hot air to give 18.5 g of a mixture of 2,4-dicarbamoylbenzoic acid and 2,5-dicarbamoylbenzoic acid as a white crystal (yield: 89%).

This mixture (16.0 g, 0.077 mol) was suspended in 80 ml of N-methyl-2-pyrrolidinone. The obtained suspension was stirred under heating at 150°C for 3 hours and cooled by allowing to stand, followed by the addition of 200 ml of

water. The crystals thus precipitated were recovered by filtration, washed with water and dried with hot air. The title compound (13.3 g) was obtained as a light brown crystal (yield: 91%).

1H-NMR (400 MHz, DMSO-d₆) δ: 7.70(1H, br s), 7.90(1H, dd, J=7.2, 1.2Hz), 8.28-8.31(2H, m), 8.32(1H, br s), 11.48(1H, br s)


5

Preparative Example 5

6-Carbamoyl-2,3-dihydro-1,4-phthalazinedione

10

15



20

4-Carbamoylphthalimide (2.00 g, 0.011 mol) was suspended in 12 ml of N-methyl-2-pyrrolidinone, followed by the dropwise addition of 0.8 ml of hydrazine hydrate. The obtained mixture was stirred at room temperature for 30 minutes, followed by the addition of 5.5 ml of 3N hydrochloric acid and 50 ml of water. The crystals thus precipitated were recovered by filtration, washed with water and dried with hot air. The title compound (2.0 g) was obtained as a light brown crystal (yield: 94%).


1H-NMR (400 MHz, DMSO-d₆) δ: 7.68(1H, br s), 8.12(1H, br d, J=8.4Hz), 8.32(1H, dd, J=8.4, 1.6Hz), 8.39(1H, br s), 8.59(1H, br s), 11.69(2H, br s)

Preparative Example 6

6-Cyano-1,4-dichlorophthalazine

35

40



45

6-Carbamoyl-2,3-dihydro-1,4-phthalazinedione (1.00 g, 0.0049 mol) was suspended in a mixture comprising 20 ml of phosphorus oxychloride and 20 ml of thionyl chloride. The obtained suspension was heated under reflux one whole day and night and distilled in a vacuum to remove the solvent. The obtained residue was dissolved in methylene chloride, followed by washing with water. The organic phase was dried over anhydrous magnesium sulfate and purified by silica gel column chromatography to give 0.76 g of the title compound as a light brown crystal (yield: 70%).


55

Preparative Example 7

1,4,6-Trichlorophthalazine

5

10



15

The title compound was prepared from 6-cyano-2,3-dihydro-1,4-phthalazinedione in a similar manner to that of
Preparative Example 3.


20 1H-NMR (400 MHz, CDCl₃) δ: 8.01(1H, dd, J=9.0, 2.0Hz), 8.29(1H, d, J=9.0Hz), 8.31(1H, d, J=2.0Hz)

Preparative Example 8

1,4-Dichloro-6-nitrophthalazine

25

30



35

The title compound was prepared from 2,3-dihydro-6-nitro-1,4-phthalazinedione in a similar manner to that of
Preparative Example 3.

40 1H-NMR (400 MHz, CDCl₃) δ: 8.02(1H, dd, J=9.0, 0.5Hz), 8.83(1H, dd, J=9.0, 2.0Hz), 9.20(1H, dd, J=2.0,
0.5Hz)

45

50


55

Preparative Example 9

5-Chloro-3-(pyrid-3-yl)methylenephthalide

5

10



15

20 A mixture comprising 5.0 g of 4-chlorophthalic anhydride, 5.5 g of 3-pyridylacetic acid hydrochloride and 0.5 g of anhydrous sodium acetate was stirred without any solvent at 200°C for 10 minutes.

Ethanol (100 ml) was added to the reaction mixture and the mixture thus obtained was cooled with ice to precipitate crystals, which were recovered by filtration to give 2.68 g of the title compound as a yellowish-orange crystal.


25 ¹H-NMR (400 MHz, DMSO-d₆) δ: 7.24(1H, s), 7.79(1H, dd, J=8.0, 2.0Hz), 7.89(1H, dd, J=8.0, 5.5Hz), 8.03(1H, dd, J=8.0, 0.5Hz), 8.35(1H, dd, J=2.0, 1.5Hz), 8.56(1H, ddd, J=8.0, 2.0, 0.54Hz), 8.74(1H, dd, J=5.5, 1.5), 9.00(1H, d, J=2.0)

Preparative Example 10

30 6-Chloro-4-(3-pyridylmethyl)-1(2H)-phthalazinone

35

40



45

5-Chloro-3-(pyrid-3-yl)methylenephthalide (2.68 g) was dissolved in 100 ml of ethanol, followed by the addition of 2.0 ml of hydrazine monohydrate. The obtained mixture was heated under reflux for 4 hours, followed by the addition of 200 ml of water. The resulting mixture was neutralized with dilute hydrochloric acid to precipitate crystals, which were recovered by filtration to give 1.87 g of the title compound as a yellow powder.

50 ¹H-NMR (400 MHz, DMSO-d₆) δ: 4.37(2H, s), 7.33(1H, ddd, J=8.5, 4.5, 1.0Hz), 7.67-7.70(1H, m), 7.89(1H, dd, J=8.0, 2.0Hz), 8.11(1H, d, J=2.0Hz), 8.26(1H, d, J=8.5Hz), 8.44(1H, dd, J=4.5, 1.5), 8.58-8.59(1H, m), 12.68(1H, s)


55

Preparative Example 11

1,6-Dichloro-4-(3-pyridylmethyl)phthalazine

5

10



15

20 6-Chloro-4-(3-pyridylmethyl)-1(2H)-phthalazinone (0.86 g) was suspended in 10 ml of phosphorus oxychloride. The obtained suspension was heated under reflux for 2 hours and freed from the phosphorus oxychloride by vacuum distillation. The residue was dissolved in tetrahydrofuran. The obtained solution was neutralized with triethylamine, followed by the addition of water. The obtained mixture was extracted with ethyl acetate. The organic phase was washed with water and a saturated aqueous solution of common salt, dried over anhydrous magnesium sulfate and freed from 25 the solvent by vacuum distillation. The residue was purified by silica gel column chromatography to give 0.49 g of the title compound as a pale yellow crystal.

1H-NMR (400 MHz, CDCl₃) δ: 4.68(2H, s), 7.23(1H, dd, J=8.0, 4.5Hz), 7.63(1H, ddd, J=8.0, 2.0, 1.5Hz), 7.90(1H, dd, J=8.5, 2.0Hz), 8.03(1H, d, J=2.0Hz), 8.28(1H, d, J=8.5Hz), 8.50(1H, dd, J=4.5, 1.5Hz), 8.66(1H, d, J=2.0Hz)


30

Preparative Example 12

4,6-Dichloro-1-(3-pyridylmethyl)phthalazine

35

40



45

50 A mixture comprising 5.0 g of 4-chlorophthalic anhydride, 5.5 g of 3-pyridylacetic acid hydrochloride and 0.5 g of anhydrous sodium acetate was stirred without any solvent at 200°C for 10 minutes.

Ethanol (100 ml) was added to the reaction mixture and the resulting mixture was cooled with ice to precipitate crystals, which were filtered out and the filtrate was concentrated in a vacuum. The obtained residue was subjected to silica gel column chromatography and the original-point fraction was removed. The effluent was concentrated in a vacuum and dissolved in 50 ml of ethanol, followed by the addition of 2.0 g of hydrazine monohydrate. The obtained mixture 55 was heated under reflux for 6 hours.


The solvent was distilled away in a vacuum and dilute aqueous hydrochloric acid was added to the residue to form a solution. This solution was neutralized with a saturated aqueous solution of sodium hydrogencarbonate and extracted with a chloroform/methanol mixture. The organic phase was dried over anhydrous magnesium sulfate and freed from the solvent by vacuum distillation. A mixture (2.27 g) comprising 7-chloro-4-(3-pyridylmethyl)-1(2H)-phthalazinone and

6-chloro-4-(3-pyridylmethyl)-1(2H)-phthalazinone was obtained as a light brown solid. This mixture (2.24 g, 8.25 mmol) was suspended in 20 ml of phosphorus oxychloride. The obtained suspension was heated under reflux for 2 hours and evaporated in a vacuum to dryness. The residue was dissolved in dichloromethane. The obtained solution was neutralized with a saturated aqueous solution of sodium carbonate and extracted with dichloromethane twice. The organic phases were combined, washed with water and a saturated aqueous solution of common salt, dried over magnesium sulfate and freed from the solvent by vacuum distillation to give 1.22 g of a crude product. This crude product was purified by silica gel column chromatography [dichloromethane/methanol (40 : 1)] to give 609 mg (2.10 mmol) of the title compound as a white crystal.

1H-NMR (400 MHz, CDCl₃) δ: 4.71(2H, s), 7.20(1H, dd, J=8.0, 5.0Hz), 7.60(1H, ddd, J=8.0, 2.0, 1.5Hz), 7.86(1H, dd, J=8.5, 2.0Hz), 8.06(1H, d, J=8.5Hz), 8.27(1H, d, J=2.0Hz), 8.47(1H, dd, J=5.0, 1.5Hz), 8.65(1H, d, J=2.0Hz)

Example 1

15 1-Chloro-4-(3-chloro-4-methoxybenzyl)amino-6-cyanophthalazine



35 6-Cyano-1,4-dichlorophthalazine (66. 2 g) prepared in Preparative Example 3 and 3-chloro-4-methoxybenzylamine (92 g) were suspended in 1200 ml of tetrahydrofuran, followed by the addition of 250 ml of triethylamine. The obtained mixture was heated under reflux for 6 hours.

The crystals thus precipitated were filtered out and the filtrate was concentrated in a vacuum. The residue was purified by silica gel column chromatography [solvent: toluene/trahydrofuran (10 : 1)] to recover a less polar product. The title compound (59 g) was obtained as a pale-yellow crystal.

40 M.p.: 213.0-214.5°C
 MASS: 359 (MH⁺)
 1H-NMR (400 MHz, CDCl₃) δ: 3.87(3H, s), 4.78(2H, d, J=5.0Hz), 5.75(1H, t, J=5.0Hz), 6.87(1H, d, J=8.5Hz), 7.31(1H, dd, J=8.5, 2.0Hz), 7.43(1H, d, J=2.0Hz), 8.05(1H, dd, J=8.5, 1.5Hz), 8.24(1H, dd, J=1.5, 1.0Hz), 8.29(1H, dd, J=8.5, 0.5Hz)

45


50

55

Example 2

4-Chloro-1-(3-chloro-4-methoxybenzyl)amino-6-cyanophthalazine

5



A more polar product prepared by repeating the same procedure as that of Example 1 was recovered to give 27 g of the title compound as a white crystal. M.p.: 122.0-123.5°C


25 MASS: 359 (MH⁺)

1H-NMR (400 MHz, CDCl₃) δ: 3.91(3H, s), 4.80(2H, d, J=5.5Hz), 5.43(1H, t, J=5.5Hz), 6.92(1H, d, J=8.5Hz), 7.33(1H, dd, J=8.5, 2.0Hz), 7.45(1H, d, J=2.0Hz), 7.89(1H, dd, J=8.5, 0.5Hz), 8.03(1H, dd, J=8.5, 1.5Hz), 8.55(1H, dd, J=1.5, 0.5Hz)

30 Example 3

4-(3-Chloro-4-methoxybenzyl)amino-6-cyano-1-(4-hydroxypiperidino)phthalazine

35



1-Chloro-4-(3-chloro-4-methoxybenzyl)amino-6-cyanophthalazine (10.0 g) prepared in Example 1 was dis-

solved in 50 ml of N-methyl-2-pyrrolidinone, followed by the addition of 43.32 g of 4-hydroxypyridine and 10 ml of diisopropylethylamine. The obtained mixture was heated at 170 for 8 hours.

Ethyl acetate was added to the reaction mixture and the obtained mixture was washed with water three times and with a saturated aqueous solution of common salt once, dried over anhydrous magnesium sulfate and freed from the solvent by vacuum distillation. The residue was purified by silica gel column chromatography [solvent: methylene chloride/methanol (30 : 1)] to give 10. 1 g of the title compound as a yellow crystal.


M.p.: 172.0-173.5°C

MASS: 424 (MH⁺)

¹⁰ ¹H-NMR (400 MHz, CDCl₃) δ: 1.70(1H, brs), 1.80-1.90(2H, m), 2.07-2.15(2H, m), 3.05-3.15(2H, m), 3.50-3.60(2H, m), 3.87(3H, s), 3.90-4.00(1H, m), 4.74(2H, d, J=5.0Hz), 5.41(1H, t, J=5.0Hz), 6.87(1H, d, J=8.5Hz), 7.29(1H, dd, J=8.5, 2.0Hz), 7.42(1H, d, J=2.0Hz), 7.95(1H, dd, J=8.5, 1.5Hz), 8.12(1H, d, J=8.5Hz), 8.21(1H, s)

Example 4

¹⁵ 4-(3-Chloro-4-methoxybenzyl)amino-6-cyano-1-(4-hydroxypiperidino)phthalazine hydrochloride



³⁵ 1-Chloro-4-(3-chloro-4-methoxybenzyl)amino-6-cyanophthalazine (10.0 g) prepared in Example 1 was dissolved in 50 ml of N-methyl-2-piperidone, followed by the addition of 43.32 g of 4-hydroxypyridine and 10 ml of diisopropylethylamine. The obtained mixture was heated at 170°C for 8 hours.

Ethyl acetate was added to the reaction mixture. The obtained mixture was washed with water three times and with a saturated aqueous solution of common salt once, dried over anhydrous magnesium sulfate and freed from the solvent by vacuum distillation. The residue was purified by silica gel column chromatography [solvent: methylene chloride/methanol (30 : 1)] to give 10.1 g of 4-(3-chloro-4-methoxybenzyl)amino-6-cyano-1-(4-hydroxypiperidino)phthalazine as a yellow crystal. This product (10.8 g) was suspended in a mixture comprising 60 ml of ethanol and 30 ml of water, followed by the addition of 30 ml of 1N aqueous hydrochloric acid. The obtained mixture was dissolved by heating and cooled by allowing to stand at room temperature.

The crystals thus precipitated were recovered by filtration and dried with hot air at 80°C overnight to give 9.37 g of the title compound as a yellow crystal.

M.p.: 217-227 (dec.) °C

MASS: 424 (MH⁺)


⁴⁵ ¹H-NMR (400 MHz, DMSO-d₆) δ: 1.61-1.70(2H, m), 1.90-1.97(2H, m), 2.97-3.04(2H, m), 3.37-3.48(2H, m), 3.70-3.79(1H, m), 3.84(3H, s), 4.70(2H, d, J=5.5Hz), 7.15(1H, d, J=8.5Hz), 7.44(1H, dd, J=8.5, 2.0Hz), 7.59(1H, d, J=2.0Hz), 8.23(1H, d, J=8.5Hz), 8.45(1H, d, J=8.5Hz), 9.33(1H, s), 10.10(1H, brs), 14.00(1H, brs)

Example 5

4-(3-Chloro-4-methoxybenzyl)amino-6-cyano-1-[4-oxo-1,4-dihydropyrid-1-yl]phthalazine

5

10



15

20

The title compound was prepared in a similar manner to that of Example 3.

M.p.: 218-219°C

MASS: 418 (MH⁺)

25 ¹H-NMR (400 MHz, DMSO-d₆) δ: 3.83(3H, s), 4.67(2H, d, J=5.6Hz), 7.11(1H, d, J=8.4Hz), 7.27(2H, dd, J=1.6Hz, 4.4Hz), 7.36(1H, dd, J=8.4, 2.0Hz), 7.48(1H, d, J=2.0Hz), 8.18-8.24(2H, m), 8.31(1H, dd, J=8.4, 1.2Hz), 8.56(2H, dd, J=1.6Hz, 4.4Hz), 9.02(1H, d, J=1.2Hz)

Example 6

30


4-(3-Chloro-4-methoxybenzyl)amino-6-cyano-1-[4-(hydroxymethyl)piperidino]phthalazine hydrochloride

35

40

45

50



The title compound was prepared in a similar manner to that of Example 4.

MASS: 438 (MH⁺)


55 ¹H-NMR (400 MHz, DMSO-d₆) δ: 1.40-1.50(2H, m), 1.61(1H, bs), 1.78-1.84(2H, m), 2.82-2.91(2H, m), 3.33(2H, d, J=6.1Hz), 3.52-3.62(2H, m), 3.83(3H, s), 4.71(2H, d, J=5.0Hz), 7.14(1H, d, J=8.4Hz), 7.45(1H, dd, J=8.4Hz, 2.4Hz), 7.61(1H, d, J=2.4Hz), 8.21(1H, d, J=8.8Hz), 8.46(1H, d, J=8.8Hz), 9.42(1H, s)

Example 7

4-(3-Chloro-4-methoxybenzyl)amino-6-cyano-1-(3-hydroxypropyl)aminophthalazine

5

10



15

The title compound was prepared in a similar manner to that of Example 3.

M.p.: 132-135°C

20 MASS: 398 (MH⁺)


1H-NMR (400 MHz, CDCl₃) δ: 1.91-1.98(2H, m), 3.40(1H, br s), 3.71-3.76(1H, m), 3.80(2H, t, J=5.6Hz), 3.81(2H, t, J=5.6Hz), 3.91(3H, s), 4.68(2H, d, J=6.4Hz), 5.30-5.34(1H, t, J=6.4Hz), 6.92(1H, d, J=8.4Hz), 7.32(1H, dd, J=8.4, 2.4Hz), 7.46(1H, d, J=2.4Hz), 7.85(1H, d, J=8.8Hz), 7.95(1H, dd, J=8.8, 1.6Hz), 8.10(1H, d, J=1.6Hz)

25 Example 8

4-(3-Chloro-4-methoxybenzyl)amino-6-cyano-1-[4-(2-hydroxyethyl)piperidino]phthalazine hydrochloride

30

35



40

45

The title compound was prepared in a similar manner to that of Example 4

M.p.: 230 (dec.) °C

MASS: 452 (MH⁺)

1H-NMR (400 MHz, DMSO-d₆) δ: 1.39-1.53(4H, m), 1.65(1H, m), 1.82(2H, m), 2.87(2H, m), 3.50(2H, t, J=6.8Hz), 3.56(2H, m), 3.85(3H, s), 4.74(2H, d, J=5.3Hz), 7.15(1H, d, J=8.6Hz), 7.49(1H, dd, J=8.6, 2.0Hz), 7.63(1H, d, J=2.0Hz), 8.23(1H, d, J=8.6Hz), 8.47(1H, dd, J=8.6, 1.5Hz), 9.53(1H, br s)


55

Example 9

4-(3-Chloro-4-methoxybenzyl)amino-6-cyano-1-(4-hydroxy-4-methylpiperidino)phthalazine hydrochloride

5

10



15

20

The title compound was prepared in a similar manner to that of Example 4.

M.p.: 230-240°C (dec.)


MASS: 438 (MH⁺)

25 ¹H-NMR (400 MHz, DMSO-d₆) δ: 1.22(3H, s), 1.61-1.71(2H, m), 1.73-1.84(2H, m), 3.18-3.33(4H, m), 3.85(3H, s), 4.76(2H, d, J=5.1Hz), 7.15(1H, d, J=8.6Hz), 7.51(1H, dd, J=8.6, 2.0Hz), 7.66(1H, d, J=2.0Hz), 8.23(1H, d, J=8.4Hz), 8.46(1H, dd, J=8.4, 1.0Hz), 9.63(1H, s)

Example 10

30 4-(3-Chloro-4-methoxybenzyl)amino-6-cyano-1-(3-hydroxypiperidino)phthalazine hydrochloride

35



40

45

The title compound was prepared in a similar manner to that of Example 4.

M.p.: 189-199°C

MASS: 424 (MH⁺)

50 ¹H-NMR (400 MHz, DMSO-d₆) δ: 1.45(1H, m), 1.71(1H, m), 1.84-1.97(2H, m), 2.86(1H, m), 2.98(1H, m), 3.32(1H, m), 3.42(1H, m), 3.83(1H, m), 3.85(3H, s), 4.76(2H, d, J=5.7Hz), 7.16(1H, d, J=8.6Hz), 7.51(1H, dd, J=8.6, 2.0Hz), 7.66(1H, d, J=2.0Hz), 8.31(1H, d, J=8.4Hz), 8.49(1H, dd, J=8.4, 1.3Hz), 9.61(1H, s)


55

Example 11

4-(3-Chloro-4-methoxybenzyl)amino-6-cyano-1-(2-pyridylmethyl)aminophthalazine dihydrochloride

5

10



15

The title compound was prepared in a similar manner to that of Example 4.

M.p.: 188-190°C

20 MASS: 431 (MH⁺)


1H-NMR (400 MHz, CD₃OD) δ: 3.83(3H, s), 4.62(2H, s), 5.05(2H, s), 7.08(1H, d, J=8.5Hz), 7.35(1H, dd, J=8.5, 2.0Hz), 7.47(1H, d, J=2.0Hz), 7.98(1H, ddd, J=8.0, 6.0, 1.5Hz), 8.16(1H, d, J=8.0Hz), 8.48(1H, dd, J=8.5, 1.5Hz), 8.57(1H, ddd, J=8.0, 8.0, 1.5Hz), 8.62(1H, d, J=8.5Hz), 8.76-8.78(1H, m), 9.06(1H, d, J=1.5Hz)

25 Example 12

4-(3-Chloro-4-methoxybenzyl)amino-6-cyano-1-(4-pyridylmethyl)aminophthalazine dihydrochloride

30

35



40

The title compound was prepared in a similar manner to that of Example 4.

M.p.: 212-214°C

MASS: 431 (MH⁺)

45 1H-NMR (400 MHz, CD₃OD) δ: 3.88(3H, s), 4.61(2H, s), 4.97(2H, s), 7.08(1H, d, J=8.5Hz), 7.34(1H, dd, J=8.5, 2.0Hz), 7.47(1H, d, J=2.0Hz), 8.11-8.14(2H, m), 8.48(1H, dd, J=8.5, 1.5Hz), 8.61(1H, d, J=8.5Hz), 8.77-8.79(2H, m), 9.04(1H, d, J=1.5Hz)

50


55

Example 13

4-(3-Chloro-4-methoxybenzyl)amino-6-cyano-1-(3-pyridylmethyl)aminophthalazine dihydrochloride

5

10



15

The title compound was prepared in a similar manner to that of Example 4.

M.p.: 195.0-196.5°C

20 MASS: 431 (MH⁺)


1H-NMR (400 MHz, DMSO-d₆) δ: 3.84(3H, s), 4.59-4.63(2H, m), 4.78-4.82(2H, m), 7.12(1H, d, J=8.5Hz), 7.40(1H, dd, J=8.5, 2.0Hz), 7.55(1H, d, J=2.0Hz), 7.92(1H, dd, J=8.0, 5.5Hz), 8.46-8.52(1H, m), 8.58(1H, dd, J=8.5, 1.5Hz), 8.77(1H, d, J=5.5Hz), 8.82-8.92(1H, m), 8.93(1H, d, J=1.5Hz), 9.36-9.42(1H, m)

25 Example 14

4-(3-Chloro-4-methoxybenzyl)amino-6-cyano-1-[N-(3-hydroxypropyl)-N-methylamino]phthalazine

30

35



40

The title compound was prepared in a similar manner as that of Example 3.

M.p: amorphous

MASS: 412 (MH⁺)

1H-NMR (400 MHz, DMSO-d₆) δ: 1.72-1.79(1H, m), 2.83(3H, s) 3.14-3.22(2H, m), 3.41-3.48(2H, m), 3.83(3H, s), 4.45(1H, t, J=4.8Hz), 4.64(2H, d, J=5.6Hz), 7.10(1H, d, J=8.0Hz), 7.36(1H, dd, J=8, 2Hz), 7.46(1H, d, J=2Hz), 7.85(1H, t, J=5.6Hz), 8.13-8.22(2H, m), 8.88(1H, d, J=1.2Hz)

50


55

Example 15

4-(3-Chloro-4-methoxybenzyl)amino-6-cyano-1-[4-(2-pyridyl)piperazin-1-yl]phthalazine dihydrochloride

5

10



15

20

The title compound was prepared in a similar manner to that of Example 4.

M.p.: 205-215 (dec.) °C


MASS: 486 (MH⁺)

²⁵ ³⁰ ³⁵ ⁴⁰ ⁴⁵ ⁵⁰ ^{1H-NMR (400 MHz, CD3OD) δ: 3.59(4H, m), 3.90(3H, s), 4.01(4H, m), 4.74(2H, s), 4.07(1H, m), 7.12(1H, d, J=8.6Hz), 7.41(1H, dd, J=8.6, 2.4Hz), 7.50(1H, d, J=9.2Hz), 7.54(1H, d, J=2.4Hz), 8.02(1H, m), 8.11(1H, m), 8.44(1H, dd, J=8.4, 1.6Hz), 8.49(1H, dd, J=8.4, 0.8Hz), 9.09(1H, dd, J=1.6, 0.8Hz)}

Example 16

4-(3-Chloro-4-methoxybenzyl)amino-6-cyano-1-[4-(2-pyrimidyl)piperazin-1-yl]phthalazine dihydrochloride

35



The title compound was prepared in a similar manner to that of Example 4.

M.p.: 205-209 (dec.) °C

MASS: 487 (MH⁺)


²⁵ ³⁰ ³⁵ ⁴⁰ ⁴⁵ ⁵⁰ ^{1H-NMR (400 MHz, CD3OD) δ: 3.52(4H, m), 3.90(3H, s), 4.17(4H, m), 4.73(2H, s), 6.94(1H, t, J=4.8Hz), 7.12(1H, d, J=8.4Hz), 7.41(1H, dd, J=8.4, 2.4Hz), 7.54(1H, d, J=2.4Hz), 8.43(1H, dd, J=8.4, 1.6Hz), 8.49(1H, dd, J=8.4, 0.6Hz), 8.57(2H, d, J=4.8Hz), 9.08(1H, dd, J=1.6, 0.6Hz)}

Example 17

1-(4-Carbamoylpiperidino)-4-(3-chloro-4-methoxybenzyl)amino-6-cyanophthalazine

5

10



15

20

The title compound was prepared in a similar manner to that of Example 3.

M.p.: 228-230 (dec.)

MASS: 451 (MH⁺)

25 ¹H-NMR (400 MHz, DMSO-d₆) δ: 1.80-1.95(4H, m), 2.30(1H, m), 2.82(2H, m), 3.44(2H, m), 3.82(3H, s), 4.64(2H, d, J=5.8Hz), 6.80(1H, br s), 7.10(1H, d, J=8.4Hz), 7.32(1H, br s), 7.35(1H, dd, J=8.4, 2.0Hz), 7.46(1H, d, J=2.0Hz), 7.91(1H, t, J=5.8Hz), 8.08(1H, d, J=8.8Hz), 8.20(1H, dd, J=8.8, 1.2Hz), 8.89(1H, d, J=1.2Hz)

Example 18


30

4-(3-Chloro-4-methoxybenzyl)amino-6-cyano-1-[4-(2'-hydroxyethyl)piperazin-1-yl]phthalazine dihydrochloride

35

40

45



50 4-(3-Chloro-4-methoxybenzyl)amino-6-cyano-1-[4-(2-hydroxyethyl)piperazin-1-yl]phthalazine (12.0 g, 26.5 mmol) prepared in a similar manner to that of Example 3 was suspended in 600 ml of acetone, followed by the addition of 60 ml of 1N hydrochloric acid. The obtained mixture was stirred at room temperature for 30 minutes to precipitate crystals, which were recovered by filtration and dried at 90°C for 6 hours to give 13.06 g of the title compound as a pale-yellow powder.

55 M.p.: 185-189°C

MASS: 453 (MH⁺)


1H-NMR (400 MHz, DMSO-d₆) δ: 3.25-3.31(2H, m), 3.37-3.52(5H, m), 3.60-3.70(4H, m), 3.85(3H, s), 3.86(2H, br t, J=5.7Hz), 4.82(2H, d, J=5.7Hz), 7.16(1H, d, J=8.8Hz), 7.53(1H, dd, J=8.8, 2.0Hz), 7.67(1H, d, J=2.0Hz), 8.33(1H, d, J=8.4Hz), 8.65(1H, dd, J=8.4, 1.1Hz), 9.67(1H, s), 11.14(br, 1H)

Example 19

4-(3-Chloro-4-methoxybenzyl)amino-6-cyano-1-(4-oxopiperidino)phthalazine hydrochloride

5

10



15

20

4-(3-Chloro-4-methoxybenzyl)amino-6-cyano-1-(4-oxopiperidino)phthalazine (565 mg, 1.21 mmol) prepared in a similar manner to that of Example 3 was dissolved in 5 ml of trifluoroacetic acid. The obtained solution was stirred at room temperature for 18 hours and evaporated in a vacuum to dryness. The residue was dissolved in dichloromethane. The obtained solution was neutralized with a saturated aqueous solution of sodium hydrogencarbonate and extracted with dichloromethane twice. The organic phases were combined, washed with water and a saturated aqueous solution of common salt, dried over magnesium sulfate and freed from the solvent by vacuum distillation. The crude product thus obtained was purified by silica gel column chromatography [ethyl acetate/hexane (3 : 1)] to give 565 mg of a pale-yellow solid. This solid was recrystallized from 50% aqueous ethanol to give 423 mg (1.00 mmol) of 4-(3-chloro-4-methoxybenzyl)amino-6-cyano-1-(4-oxopiperidino)phthalazine. This compound was converted into a hydrochloride in the same manner as that employed in Example 4 for the formation of hydrochloride.

M.p.: 206°C (dec.)

MASS: 422 (MH⁺)

¹H-NMR (400 MHz, DMSO-d₆) δ: 2.62-2.68(4H, m), 3.55-3.61(4H, m), 3.85(3H, s), 4.77(2H, d, J=5.5Hz), 7.15(1H, d, J=8.5Hz), 7.49(1H, dd, J=8.5, 2.0Hz), 7.64(1H, d, J=2.0Hz), 8.40(1H, d, J=8.5Hz), 8.50(1H, dd, J=8.5, 1.5Hz), 9.55(1H, d, J=1.5Hz)


Example 20

40 1-(4-Carboxypiperidino)-4-(3-chloro-4-methoxybenzyl)amino-6-cyanophthalazine hydrochloride

45

50

55



1-Chloro-4-(3-chloro-4-methoxybenzyl)amino-6-cyanophthalazine (2 g) prepared in Example 1 and t-butyl iso-

nipectate (2 g) were dissolved in 20 ml of N-methyl-2-pyrrolidone. The obtained solution was heated at 170°C for 5 hours and cooled, followed by the addition of water. The obtained mixture was extracted with ethyl acetate. The organic phase was washed with water, dried over anhydrous magnesium sulfate and concentrated in a vacuum. The obtained residue was subjected to silica gel column chromatography and eluted with toluene/tetrahydrofuran (10 : 1) to give 1.6 g of 1-(4-tert-butoxycarbonylpiperidino)-4-(3-chloro-4-methoxybenzyl)amino-6-cyanophthalazine.

5 1-(4-tert-Butoxycarbonylpiperidino)-4-(3-chloro-4-methoxybenzyl)amino-6-cyanophthalazine (1.2 g) was stirred in 20 ml of formic acid at room temperature for 20 hours. The resulting mixture was concentrated in a vacuum and the obtained residue was subjected to silica gel column chromatography and eluted with dichloromethane/methanol (10 : 1) to give 1.05 g of the title compound.

10 M.p.: >270°C

MASS: 452 (MH⁺)


15 1H-NMR (400 MHz, DMSO-d6) δ: 1.88-1.93(2H, m), 1.96-2.03(2H, m), 2.50-2.59(1H, m), 2.92-3.01(2H, m), 3.50-3.58(2H, m), 3.85(3H, s), 4.74(2H, d, J=5.2Hz), 7.16(1H, d, J=8.4Hz), 7.48(1H, dd, J=8.4, 2.4Hz), 7.63(1H, d, J=2.4Hz), 8.26(1H, d, J=8.4Hz), 8.46(1H, dd, J=8.4, 1.2Hz), 9.49(1H, d, J=1.2Hz)

15

Example 21

4-(3-Chloro-4-methoxybenzyl)amino-6-cyano-1(2H)-phthalazinone

20



1-Chloro-4-(3-chloro-4-methoxybenzyl)amino-6-cyanophthalazine (1.0 g) prepared in Example 1 was dissolved in 10 ml of N-methyl-2-piperidone, followed by the addition of 0.26 ml of acetic acid and 2.1 ml of diisopropylethylamine. The obtained mixture was stirred at 170°C for 7 hours, followed by the addition of 100 ml of water. The crystals thus precipitated were recovered by filtration.

35 The crystals were recrystallized from ethanol/water to give 0.6 g of the title compound as a yellow crystal.

M.p.: 292.5-294°C

MASS: 341 (MH⁺)


40 1H-NMR (400 MHz, DMSO-d6) δ: 3.81(3H, s), 4.36(2H, d, J=5.5Hz), 7.07(1H, d, J=8.5Hz), 7.29(1H, dd, J=8.5,

2.0Hz), 7.30(1H, t, J=5.5Hz), 7.41(1H, d, J=2.0Hz), 8.19(1H, dd, J=8.0, 1.0Hz), 8.32(1H, d, J=8.0Hz), 8.73(1H, d, J=1.0Hz), 11.86(1H, s)

Example 22

45 2-tert-Butoxycarbonylmethyl-4-(3-chloro-4-methoxybenzyl)amino-6-cyano-1(2H)-phthalazinone

50




5 4-(3-Chloro-4-methoxybenzyl)amino-6-cyano-1(2H)-phthalazinone (0.20 g) prepared in Example 21 was dissolved in 5 ml of N-methyl-2-pyrrolidinone, followed by the addition of 0.14 g of t-butyl bromoacetate and 0.24 g of potassium carbonate. The obtained mixture was stirred at 80°C for 4 hours and poured into water, followed by extraction with ethyl acetate. The organic phase was washed with water twice and with a saturated aqueous solution of common salt, dried over anhydrous magnesium sulfate and freed from the solvent by vacuum distillation. The title compound (0.41 g) was obtained as a yellow crystal.

M.p.: 173.5-175°C
MASS: 454 (MH+)
10 1H-NMR (400 MHz, DMSO-d6) δ: 1.49(9H, s), 3.90(3H, s), 4.37(2H, d, J=5.0Hz), 4.91(2H, d, J=5.0Hz), 6.90(1H, d, J=8.5Hz), 7.25(1H, dd, J=8.5, 2.0Hz), 7.42(1H, d, J=2.0Hz), 7.93(1H, dd, J=8.0, 1.5Hz), 8.00(1H, d, J=1.5Hz), 8.53(1H, d, J=8.0Hz)

Example 23

15 2-Carboxymethyl-4-(3-chloro-4-methoxybenzyl)amino-6-cyano-1(2H)-phthalazinone




30 Trifluoroacetic acid (5 ml) was added to 0.41 g of the t-butyl ester prepared in Example 22. The obtained mixture was stirred at room temperature for one hour and freed from the trifluoroacetic acid by vacuum distillation. The obtained residue was recrystallized from ethanol/water to give 0.06 g of the title compound as a yellow crystal.

M.p.: 173-175°C
MASS: 399 (MH+)
35 1H-NMR (400 MHz, DMSO-d6) δ: 3.81(3H, s), 4.34(2H, d, J=5.5Hz), 4.62(2H, s), 7.06(1H, d, J=8.5Hz), 7.32(1H, dd, J=8.5, 2.0Hz), 7.43(1H, t, J=5.5Hz), 7.45(1H, d, J=2.0Hz), 8.22(1H, dd, J=8.0Hz, 1.0Hz), 8.34(1H, d, J=8.0Hz), 8.74(1H, d, J=1.0Hz), 12.95(1H, br s)

Example 24

40 4-(3-Chloro-4-methoxybenzyl)amino-6-cyano-2-[3-(tetrahydropyran-2-yloxy)propyl]-1(2H)-phthalazinone




55 4-(3-Chloro-4-methoxybenzyl)amino-6-cyano-1(2H)-phthalazinone (0.20 g) prepared in Example 21 was dissolved in 5 ml of N-methyl-2-pyrrolidinone, followed by the addition of 0.24 g of 3-bromopropyl 2-tetrahydropyranyl ether and 0.24 g of potassium carbonate. The obtained mixture was stirred at 50°C for 4 hours and poured into water, followed by extraction with ethyl acetate. The organic phase was washed with water twice and with a saturated aqueous solution of common salt, dried over anhydrous magnesium sulfate and freed from the solvent by vacuum distillation.

The residue was purified by silica gel column chromatography [solvent: n-hexane/ethyl acetate (1 : 1)] to give 0.20 g of the title compound as a yellow crystal.

5 ¹H-NMR (400 MHz, CDCl₃) δ: 1.44-1.83(6H, m), 2.08-2.17(2H, m), 3.45-3.51(2H, m), 3.81-3.87(2H, m),
 3.89(3H, s), 4.17-4.30(2H, m), 4.46(2H, d, J=5.5Hz), 4.57-4.59(1H, m), 5.02(1H, t, J=5.5Hz), 6.90(1H, d, J=8.5Hz),
 7.28(1H, dd, J=8.5, 2.0Hz), 7.44(1H, d, J=2.0Hz), 7.93(1H, dd, J=8.0, 1.5Hz), 8.06(1H, dd, J=1.5, 1.0Hz), 8.55(1H, dd,
 J=8.0, 0.5Hz)

Example 25

10 4-(3-Chloro-4-methoxybenzyl)amino-6-cyano-2-(3-hydroxypropyl)-1(2H)-phthalazinone




Methanol (20 ml) and 1N hydrochloric acid (2 ml) were added to the 4-(3-chloro-4-methoxybenzyl)amino-6-cyano-2-[3-(tetrahydropyran-2-yloxy)propyl]-1(2H)-phthalazinone (0.20 g) prepared in Example 24. The obtained mixture was stirred at room temperature for 3 hours.

The solvent was distilled away in a vacuum and the residue was recrystallized from ethanol/water to give 0.14 g of the title compound as a yellow crystal. M.p.: 191.5-193.0°C
 MASS: 399 (MH⁺)
 30 ¹H-NMR (400 MHz, DMSO-d₆) δ: 1.79(2H, quint, J=6.0Hz), 3.40(2H, q, J=6.0Hz), 3.81(3H, s), 3.99(2H, t, J=6.0Hz), 4.36(2H, d, J=5.5Hz), 7.07(1H, d, J=8.5Hz), 7.33(1H, dd, J=8.5, 2.0Hz), 7.45(1H, t, J=5.0Hz), 7.46(1H, d, J=2.0Hz), 8.19(1H, dd, J=8.0, 1.5Hz), 8.34(1H, d, J=8.0Hz), 8.71(1H, d, J=1.5Hz)

Example 26

35 6-Cyano-1-(4-hydroxypiperidino)-4-(3,4-methylenedioxybenzyl)aminophthalazine hydrochloride



The title compound was prepared from 1-chloro-6-cyano-4-(3,4-methylenedioxybenzyl)aminophthalazine prepared in a similar manner to that of Example 1 in a similar manner to that of Example 4.
 MASS: 404 (MH⁺)

EP 0 722 936 A1

1H-NMR (400 MHz, DMSO-d₆) δ: 1.52-1.70(2H, m), 1.86-1.95(2H, m), 2.94-3.02(2H, m), 3.38-3.46(2H, m), 3.69-3.75(1H, m), 4.73(2H, d, J=5.0Hz), 6.87(1H, d, J=8.0Hz), 7.04(1H, dd, J=8, 1.6Hz), 7.16(1H, d, J=1.6Hz), 8.19(1H, d, J=8.4Hz), 8.44(1H, d, J=8.4Hz), 9.69(1H, s)

5 Example 27

4-(3-Chloro-4-methoxybenzyl)amino-1,6-dichlorophthalazine

10

15



20

The title compound was prepared from 1,4,6-trichlorophthalazine prepared in Preparative Example 7 in a similar manner to that of Example 1.

M.p.: 197-198.5°C

MASS: 368 (MH⁺)

25

1H-NMR (400 MHz, CDCl₃) δ: 3.89(3H, s), 4.78(2H, d, J=5.5Hz), 5.32(1H, t, J=5.5Hz), 6.89(1H, d, J=8.5Hz), 7.32(1H, dd, J=8.5, 2.0Hz), 7.45(1H, d, J=2.0Hz), 7.77(1H, d, J=2.0Hz), 7.82(1H, dd, J=9.0, 2.0Hz), 8.15(1H, d, J=9.0Hz)

Example 28


30

1-(3-Chloro-4-methoxybenzyl)amino-4,6-dichlorophthalazine

35

40

45



50

The title compound was prepared from 1,4,6-trichlorophthalazine prepared in Preparative Example 7 in a similar manner to that of Example 2.

M.p.: 168-169.5°C

MASS: 368 (MH⁺)

55


1H-NMR (400 MHz, CDCl₃) δ: 3.90(3H, s), 4.78(2H, d, J=5.5Hz), 5.30(1H, t, J=5.5Hz), 6.91(1H, d, J=8.5Hz), 7.33(1H, dd, J=8.5, 2.0Hz), 7.45(1H, d, J=2.0Hz), 7.72(1H, d, J=9.0Hz), 7.78(1H, dd, J=9.0, 2.0Hz), 8.18(1H, d, J=2.0Hz)

Example 29

6-Chloro-4-(3-chloro-4-methoxybenzyl)amino-1-(3-hydroxypyrrolidino)phthalazine

5

10



15

In a similar manner to that of Example 3, the title compound was prepared from 4-(3-chloro-4-methoxybenzyl)amino-1,6-dichlorophthalazine prepared in Example 27.

M.p.: 191-193°C

MASS: 419 (MH⁺)

²⁵ ¹H-NMR (400 MHz, CDCl₃) δ: 2.01-2.08(1H, m), 2.14-2.24(1H, m), 3.56-3.64(1H, m), 3.73(1H, dt, J=14Hz, 4Hz), 3.82(1H, dd, J=6Hz, 16Hz), 3.88(3H, s), 3.94(1H, dt, J=14Hz, 16Hz), 4.58-4.62(1H, m), 4.69(2H, d, J=6Hz), 4.83-4.90(1H, br t), 6.89(1H, d, J=8.4Hz), 7.31(1H, dd, J=2.2Hz, 8.4Hz), 7.45(1H, d, J=2.2Hz), 7.68(1H, dd, J=2.0Hz, 8.8Hz), 7.72(1H, d, J=2.0Hz), 8.10(1H, d, J=8.8Hz)

Example 30


30

(R)-6-Chloro-4-(3-chloro-4-methoxybenzyl)amino-1-[2-(hydroxymethyl)pyrrolidino]phthalazine hydrochloride

35

40

45



50

In a similar manner to that of Example 4, the title compound was prepared from 4-(3-chloro-4-methoxybenzyl)amino-1,6-dichlorophthalazine prepared in Example 27.

M.p.: 163-165°C

MASS: 433 (MH⁺)

⁵⁵ ¹H-NMR (400 MHz, CDCl₃) δ: 1.80-1.95(1H, m), 1.95-2.04(1H, m), 2.15-2.24(1H, m), 3.42-3.48(1H, m), 3.75(1H, dd, J=16Hz, 8Hz), 3.86(1H, dd, J=6Hz, 16Hz), 3.90(3H, s), 3.90-3.97(1H, m), 4.70(2H, d, J=6Hz), 4.70-4.77(1H, m), 4.83(1H, br, t, J=6Hz), 6.91(1H, d, J=8.4Hz), 7.31(1H, dd, J=8.4, 2.2Hz), 7.45(1H, d, J=2.2Hz), 7.69(1H, dd, J=8.4Hz, 2.0Hz), 7.72(1H, d, J=2.0Hz), 8.08(1H, d, J=2.0Hz)

Example 31


6-Chloro-4-(3-chloro-4-methoxybenzyl)amino-1-(imidazol-1-yl)phthalazine

5

10

15

20



In a similar manner to that of Example 3, the title compound was prepared from 4-(3-chloro-4-methoxybenzyl)amino-1,6-dichlorophthalazine prepared in Example 27.


M.p.: 221-222.5°C

²⁵ ³⁰ ³⁵ ⁴⁰ ⁴⁵ ⁵⁰ ⁵⁵ ^{1H-NMR} (400 MHz, CDCl₃) δ: 3.91(3H, s), 4.86(2H, d, J=5.5Hz), 5.56(1H, t, J=5.5Hz), 6.93(1H, d, J=8.5Hz), 7.31(1H, br s), 7.36(1H, dd, J=8.5, 2.0Hz), 7.41-7.42(1H, m), 7.48(1H, d, J=2.0Hz), 7.67(1H, d, J=9.0Hz), 7.81(1H, dd, J=9.0, 2.0Hz), 7.99(1H, br s)

Example 32

6-Chloro-4-(3-chloro-4-methoxybenzyl)amino-1-(4-hydroxypiperidino)phthalazine hydrochloride

35



In a similar manner to that of Example 4, the title compound was prepared from 4-(3-chloro-4-methoxybenzyl)amino-1,6-dichlorophthalazine prepared in Example 27.

M.p.: 229-232 (dec.) °C

MASS: 433 (MH⁺)

⁴⁰ ⁴⁵ ⁵⁰ ⁵⁵ ^{1H-NMR} (400 MHz, DMSO-d₆) δ: 1.60-1.70(2H, m), 1.86-1.96(2H, m), 2.95-3.06(2H, m), 3.38-3.48(2H, m),

EP 0 722 936 A1


3.69-3.78(1H, m), 3.92(3H, s), 4.68(2H, d, J=4.6Hz), 7.13(1H, d, J=8.8Hz), 7.43(1H, d, J=8.8Hz), 7.58(1H, s), 8.06-8.15(2H, m), 9.01(1H, s)

Example 33

5

1.6-Bis-(4-hydroxypiperidino)-4-(3-chloro-4-methoxybenzyl)aminophthalazine hydrochloride

10



15

20

The title compound was prepared in a similar manner to that of Example 32 as a more polar product.

MASS: 498 (MH⁺)

25 1H-NMR (400 MHz, DMSO-d₆) δ: 1.40-1.51(2H, m), 1.55-1.65(2H, m), 1.80-1.91(4H, m), 2.78-2.85(2H, m), 3.03-3.11(2H, m), 3.27-3.34(2H, m), 3.56-3.66(1H, m), 3.66-3.25(1H, m), 3.76-3.82(2H, m), 3.80(3H, s), 4.60(2H, d, J=5.3Hz), 4.68(1H, d, J=4.1Hz), 4.22(1H, d, J=4.1Hz), 7.34(1H, d, J=8.6Hz), 7.28(1H, dd, J=8.6Hz, 2.0Hz), 7.38-7.41(2H, m), 7.43(1H, t, J=5.5Hz), 7.51(1H, dd, J=9Hz, 2.0Hz), 7.72(1H, d, J=9.0Hz)

30 Example 34


6-Chloro-4-(3-chloro-4-methoxybenzyl)amino-1-

Example 34

35

6-Chloro-4-(3-chloro-4-methoxybenzyl)amino-1-morpholinophthalazine hydrochloride

40



45

50

In a similar manner to that of Example 4, the title compound was prepared from 4-(3-chloro-4-methoxybenzyl)amino-1,6-dichlorophthalazine prepared in Example 27.

55 M.p.: 255-261 (dec.) °C

MASS: 419 (MH⁺)


1H-NMR (400 MHz, DMSO-d₆) δ: 3.20-3.23(4H, m), 3.82-3.96(4H, m), 3.85(3H, s), 4.74(2H, d, J=6.0Hz), 7.15(1H, d, J=8.8Hz), 7.48(1H, dd, J=8.8, 2.0Hz), 7.63(1H, d, J=2.0Hz), 8.13(1H, dd, J=8.8, 2.0Hz), 8.21(1H, d, J=8.8Hz), 9.16(1H, d, J=2.0Hz), 10.50(1H, br t), 13.97(1H, br s)

Example 35

6-Chloro-4-(3-chloro-4-methoxybenzyl)amino-1-(3-hydroxypropyl)aminophthalazine

5

10



15

In a similar manner to that of Example 3, the title compound was prepared from 4-(3-chloro-4-methoxybenzyl)amino-1,6-dichlorophthalazine prepared in Example 27.

M.p.: 131-138°C

20 MASS: 407 (MH⁺)


¹H-NMR (400 MHz, CDCl₃) δ: 1.83-1.94(2H, m), 3.75(2H, t, J=5.4Hz), 3.80(2H, t, J=5.4Hz), 3.90(3H, s), 4.59(1H, br t, J=4.8Hz), 4.66(2H, d, J=4.8Hz), 5.14(1H, br t), 6.91(1H, d, J=8.4Hz), 7.32(1H, dd, J=8.4, 2.4Hz), 7.45(1H, d, J=2.4Hz), 7.69(2H, s), 7.72(1H, d, J=1.6Hz)

25 Example 36

6-Chloro-4-(3-chloro-4-methoxybenzyl)amino-1-[4-(hydroxymethyl)piperidino]phthalazine

30

35



40

45

In a similar manner to that of Example 3, the title compound was prepared from 4-(3-chloro-4-methoxybenzyl)amino-1,6-dichlorophthalazine prepared in Example 27.

M.p.: 128-131°C

MASS: 447 (MH⁺)

¹H-NMR (400 MHz, CDCl₃) δ: 1.48-1.63(3H, m), 1.76(1H, m), 1.92(2H, m), 3.01(2H, dt, J=12.3, 2.0Hz), 3.59-3.67(4H, m), 3.89(3H, s), 4.74(2H, d, J=5.1Hz), 4.99(1H, br t, J=5.1Hz), 6.89(1H, d, J=8.4Hz), 7.32(1H, dd, J=8.4, 2.2Hz), 7.45(1H, d, J=2.2Hz), 7.70(1H, dd, J=8.6, 1.8Hz), 7.73(1H, d, J=1.8Hz), 7.99(1H, d, J=8.6Hz)


55

Example 37

6-Chloro-4-(3-chloro-4-methoxybenzyl)amino-1-[4-(2-hydroxyethyl)piperidino]phthalazine

5

10



15

20

In a similar manner to that of Example 3, the title compound was prepared from 4-(3-chloro-4-methoxybenzyl)amino-1,6-dichlorophthalazine prepared in Example 27.

M.p.: 153-155°C

25 MASS: 461 (MH⁺)

¹H-NMR (400 MHz, CDCl₃) δ: 1.41(br s), 1.54(2H, m), 1.60-1.76(3H, m), 1.88(2H, m), 2.98(2H, dt, J=12.5, 1.8Hz), 3.59(2H, m), 3.78(2H, br t, J=6.2Hz), 3.89(3H, s), 4.74(2H, d, J=5.3Hz), 5.00(1H, br t, J=5.3Hz), 6.89(1H, d, J=8.4Hz), 7.31(1H, dd, J=8.4, 2.2Hz), 7.45(1H, d, J=2.2Hz), 7.69(1H, dd, J=8.8, 2.0Hz), 7.73(1H, d, J=2.2Hz), 7.98(1H, d, J=8.8Hz)

30

Example 38

6-Chloro-4-(3-chloro-4-methoxybenzyl)amino-1-ethoxyphthalazine

35

40



45

A solution of 120 mg of 60% oily sodium hydride in 20 ml of ethanol was added to 1.0 g of 4-(3-chloro-4-methoxybenzyl)amino-1,6-dichlorophthalazine prepared in Example 27. The obtained mixture was heated at 150°C in a sealed tube overnight, cooled and concentrated in a vacuum. The residue was dissolved in ethyl acetate. The obtained solution was washed with water and a saturated aqueous solution of common salt, dried over anhydrous magnesium sulfate and concentrated in a vacuum. The obtained residue was subjected to silica gel column chromatography and eluted with dichloromethane/methanol (50 : 1) to give 0.9 g of the title compound.

M.p.: 111-115°C

55 MASS: 387 (MH⁺)

¹H-NMR (400 MHz, DMSO-d₆) δ: 1.46(3H, t, J=7.2Hz), 3.82(3H, s), 4.43(2H, q, J=7.2Hz), 4.59(2H, d, J=5.6Hz), 7.08(1H, d, J=8.4Hz), 7.33(1H, dd, J=8.4, 2.0Hz), 7.44(1H, d, J=2.0Hz), 7.65(1H, t, J=5.6Hz), 7.90(1H, dd, J=8.8, 2.0Hz), 8.03(1H, d, J=8.8Hz), 8.45(1H, d, J=2.0Hz)


Example 39

6-Chloro-4-(3-chloro-4-methoxybenzyl)amino-1-(3-hydroxypropyloxy)phthalazine

5

10

15



60% Sodium hydride (0.12 g, 3.0 mmol) was added to 8 ml of 1,3-propanediol. The obtained mixture was stirred at room temperature for one hour, followed by the addition of 1.0 g (2.7 mmol) of the compound prepared in Example 27. The obtained mixture was stirred at 150°C for one hour, followed by the addition of water. The resulting mixture was extracted with ethyl acetate. The organic phase was washed with water and a saturated aqueous solution of common salt, dried over anhydrous magnesium sulfate and freed from the solvent by distillation. The residue was purified by silica gel column chromatography [solvent: dichloromethane/methanol (30 : 1)] and recrystallized from aqueous ethanol to give 0.58 g of the title compound as white needles.

25 M.p.: 124-126°C

MASS: 408 (MH⁺)

1H-NMR (400 MHz, CDCl₃) δ: 2.11(2H, quintet, J=6.0Hz), 3.22(1H, br s), 3.82(2H, br), 3.87(3H, s), 4.67(2H, d, J=5.3Hz), 4.70(2H t, J=6.0Hz), 5.08(1H, t, J=5.3Hz), 6.85(1H, d, J=8.4Hz), 7.28(1H, dd, J=8.4, 2.2Hz), 7.42(1H, d, J=2.2Hz), 7.69(1H, dd, J=8.8, 1.8Hz), 7.75(1H, d, J=1.8Hz), 8.05(1H, d, J=8.8Hz)

30


Example 40

6-Chloro-4-(3-chloro-4-methoxybenzyl)amino-1-[N-(3-hydroxypropyl)-N-methylamino]phthalazine

35

40

45



The compound (1.0 g, 2.7 mmol) prepared in Example 27 was dissolved in 9 ml of N-methyl-2-pyrrolidone, followed by the addition of 0.7 g (4.1 mmol) of N-methylpropanolamine hydrobromide and 1.14 g (8.2 mmol) of anhydrous potassium carbonate. The obtained mixture was stirred at 170°C for 7.5 hours, followed by the addition of water. The resulting mixture was extracted with ethyl acetate. The organic phase was washed with water and a saturated aqueous solution of common salt, dried over anhydrous magnesium sulfate and freed from the solvent by distillation. The residue was purified by silica gel column chromatography [solvent: dichloromethane/methanol (20 : 1)] and crystallized from dichloromethane/ether to give 37 mg of the title compound as white needles.

55 M.p.: 115-117°C

MASS: 421 (MH⁺)

1H-NMR (400 MHz, CDCl₃) δ: 1.95(2H, quintet, J=6.0Hz), 2.85(1H, br s), 2.99(3H, s), 3.51(2H, t, J=6.0Hz),

EP 0 722 936 A1


3.75(2H, t, J=6.0Hz), 3.90(3H, s), 4.74(2H, d, J=5.3Hz), 4.95(1H, br), 6.91(1H, d, J=8.4Hz), 7.33(1H, dd, J=8.4, 2.0Hz),
7.46(1H, d, J=2.2Hz), 7.72(1H, dd, J=9.3, 2.0Hz), 7.72(1H, d, J=2.0Hz), 8.05(1H, d, J=9.3Hz)

Example 41

5

6-Chloro-4-(3-chloro-4-methoxybenzyl)amino-1-(4-oxopiperidino)phthalazine hydrochloride

10



15

20

25 In a similar manner to that of Example 19, the title compound was prepared from the compound prepared in
Example 27.
M.p.: 197 (dec.) °C
MASS: 431 (MH+)
30 1H-NMR (400 MHz, DMSO-d6) δ: 2.62-2.66(4H, m), 3.57-3.61(4H, m), 3.85(3H, s), 4.73(2H, d, J=6.0Hz),
7.16(1H, d, J=8.5Hz), 7.45(1H, dd, J=8.5, 2.0Hz), 7.60(1H, d, J=2.0Hz), 8.17(1H, dd, J=9.0, 2.0Hz), 8.28(1H, d,
J=9.0Hz), 9.02(1H, br s)


Example 42

35 6-Chloro-4-(3-chloro-4-methoxybenzyl)amino-1-(4-ethoxycarbonylpiperidino)phthalazine

40

45

50



55 In a similar manner to that of Example 3, the title compound was prepared from the compound prepared in
Example 27.
M.p.: 162-164.5°C
MASS: 489 (MH+)
1H-NMR (400 MHz, CDCl₃) δ: 1.29(3H, t, J=7.0Hz), 1.96-2.14(4H, m), 2.50-2.58(1H, m), 2.99-3.07(2H, m),
3.57-3.63(2H, m), 3.91(3H, s), 4.19(2H, q, J=7.0Hz), 4.75(2H, d, J=5.0Hz), 4.92(1H, t, J=5.0Hz), 6.91(1H, d, J=8.5Hz),

7.32(1H, dd, J=8.5, 2.0Hz), 7.46(1H, d, J=2.0Hz), 7.70(1H, d, J=2.0Hz), 7.71(1H, dd, J=8.0, 2.0Hz), 7.99(1H, d, J=8.0Hz)

Example 43


5

1-(4-Carboxypiperidino)-6-chloro-4-(3-chloro-4-methoxybenzyl)aminophthalazine

10

15

20



Methanol (50 ml), tetrahydrofuran (50 ml) and 1N aqueous solution (10 ml) of sodium hydroxide were added to 25 3.00 g of the compound prepared in Example 42. The obtained mixture was stirred at room temperature overnight and freed from the solvent by vacuum distillation. The residue was dissolved in 100 ml of water, followed by the addition of 10 ml of 1N hydrochloric acid. The crystals thus precipitated were recovered by filtration to give 2.76 g of the title compound as a pale-yellow crystal.

M.p.: 239.5-242°C (dec.)

30 MASS: 489 (MH⁺)

1H-NMR (400 MHz, DMSO-d₆) δ: 1.78-1.90(2H, m), 1.93-2.00(2H, m), 2.40-2.50(1H, m), 2.83-2.90(2H, m), 3.35-3.45(2H, m), 3.82(3H, s), 4.61(2H, d, J=5.5Hz), 7.09(1H, d, J=8.5Hz), 7.33(1H, dd, J=8.5, 2.0Hz), 7.43(1H, d, J=2.0Hz), 7.75(1H, t, J=5.5Hz), 7.88(1H, dd, J=9.0, 2.0Hz), 7.98(1H, d, J=9.0Hz), 8.44(1H, d, J=2.0Hz)


35 Example 44

1-[N-(3-Carboxypropyl)-N-methylamino]-6-chloro-4-(3-chloro-4-methoxybenzyl)aminophthalazine

40

45

50



6-Chloro-1-[N-(3-ethoxycarbonylpropyl)-N-methylamino]-4-(3-chloro-4-methoxybenzyl)aminophthalazine was prepared from the compound prepared in Example 27 in a similar manner to that of Example 3 and further converted into the title compound in a similar manner to that of Example 43.

55 M.p.: 248-250 (dec.) °C


1H-NMR (400 MHz, DMSO-d₆) δ: 1.76-1.86(1H, m), 2.06-2.14(1H, m), 2.80(3H, s), 3.06-3.14(2H, m), 3.81(3H, s), 4.59(2H, d, J=6Hz), 7.08(1H, d, J=8.4Hz), 7.34(1H, dd, J=8.4, 2.2Hz), 7.44(1H, d, J=2.2Hz), 7.86-7.95(2H, m), 8.02(1H, d, J=8.8Hz), 8.54(1H, d, J=2.0Hz)

Example 45

6-Chloro-1-(4-ethoxycarbonylpiperidino)-4-(3,4-methylenedioxybenzyl)aminophthalazine

5

10



15

20

A mixture (4.83 g) comprising 1,6-dichloro-4-(3,4-methylenedioxybenzyl)aminophthalazine and 4,6-dichloro-1-(3,4-methylenedioxybenzyl)aminophthalazine was prepared from 1,4,6-trichlorophthalazine (3.38 g) prepared in Preparative Example 7 and piperonylamine (2.21 g) in a similar manner to that of Example 1. The title compound (0.22 g) was prepared from 0.8 g of the mixture in a similar manner to that of Example 3 as a less polar product.


²⁵ ³⁰ ³⁵ ⁴⁰ ⁴⁵ ⁵⁰

¹H-NMR (400 MHz, CDCl₃) δ: 1.28(3H, t, J=7.0Hz), 1.90-2.10(4H, m), 2.46-2.55(1H, m), 2.96-3.05(2H, m), 3.53-3.60(2H, m), 4.16(2H, q, J=7.0Hz), 4.70(2H, d, J=5.0Hz), 5.21(1H, t, J=5.0Hz), 5.91(2H, s), 6.73(1H, d, J=8.0Hz), 6.87(1H, dd, J=8.0, 1.5Hz), 6.91(1H, d, J=1.5Hz), 7.68(1H, dd, J=8.5, 2.0Hz), 7.78(1H, d, J=2.0Hz), 7.96(1H, d, J=8.5Hz)

Example 46

6-Chloro-4-(4-ethoxycarbonylpiperidino)-1-(3,4-methylenedioxybenzyl)aminophthalazine

35



45

50

The title compound (0.21 g) was prepared by repeating the same procedure as that of Example 45 and recovering a more polar product.

¹H-NMR (400 MHz, CDCl₃) δ: 1.25(3H, t, J=7.0Hz), 1.96-2.14(4H, m), 2.48-2.57(1H, m), 3.09-3.13(2H, m), 3.54-3.61(2H, m), 4.18(2H, q, J=7.0Hz), 4.71(2H, d, J=5.0Hz), 5.13(1H, t, J=5.0Hz), 5.93(2H, s), 6.75(1H, d, J=8.0Hz), 6.88(1H, dd, J=8.0, 1.5Hz), 6.92(1H, d, J=1.5Hz), 7.65(1H, dd, J=9.0, 2.0Hz), 7.71(1H, d, J=9.0Hz), 7.97(1H, d, J=2.0Hz)


Example 47

1-(4-Carboxypiperidino)-6-chloro-4-(3,4-methylenedioxybenzyl)aminophthalazine

5

10

15



20

In a similar manner to that of Example 43, the title compound was prepared from the compound prepared in Example 45.

M.p.: 165-167°C

MASS: 441 (MH⁺)

25

¹H-NMR (400 MHz, DMSO-d₆) δ: 1.80-1.91(2H, m), 1.94-2.01(2H, m), 2.43-2.52(1H, m), 2.86-2.94(2H, m), 3.40-3.50(2H, m), 4.61(2H, d, J=5.0Hz), 5.98(2H, s), 6.87(1H, d, J=8.0Hz), 6.90(1H, dd, J=8.0, 1.0Hz), 7.00(1H, d, J=1.0Hz), 7.95(1H, br d, J=9.0Hz), 8.03(1H, d, J=9.0Hz), 9.58(1H, br s)

30


Example 48

4-(4-Carboxypiperidino)-6-chloro-1-(3,4-methylenedioxybenzyl)aminophthalazine

35

40

45



50

In a similar manner to that of Example 43, the title compound was prepared from the compound prepared in Example 46.

M.p.: 152-154°C

MASS: 441 (MH⁺)

55


¹H-NMR (400 MHz, DMSO-d₆) δ: 1.80-1.90(2H, m), 1.94-2.01(2H, m), 2.41-2.50(1H, m), 2.85-2.92(2H, m), 3.35-3.43(2H, m), 4.62(2H, d, J=5.0Hz), 5.96(2H, s), 6.84(1H, d, J=8.0Hz), 6.88(1H, dd, J=8.0, 1.5Hz), 6.97(1H, d, J=1.5Hz), 7.89(1H, d, J=2.0Hz), 7.96(1H, dd, J=9.0, 2.0Hz), 8.39(1H, d, J=9.0Hz)

Example 49

1-Chloro-4-(3-chloro-4-methoxybenzyl)amino-6-nitrophthalazine

5

10



15

In a similar manner to that of Example 1, the title compound was prepared from 1,4-dichloro-6-nitrophthalazine prepared in Preparative Example 8.

M.p.: 217.0-217.5°C

20 MASS: 379 (MH⁺)


¹H-NMR (400 MHz, CDCl₃) δ: 3.90(3H, s), 4.83(2H, d, J=5.5Hz), 5.73(1H, t, J=5.5Hz), 6.91(1H, d, J=8.0Hz), 7.35(1H, dd, J=8.0, 2.0Hz), 7.47(1H, d, J=2.0Hz), 8.38(1H, d, J=9.0Hz), 8.65(1H, dd, J=9.0, 2.0Hz), 8.73(1H, d, J=2.0Hz)

25 Example 50

4-Chloro-1-(3-chloro-4-methoxybenzyl)amino-6-nitrophthalazine

30

35



40

In a similar manner to that of Example 2, the title compound was prepared from 1,4-dichloro-6-nitrophthalazine prepared in Preparative Example 8.

M.p.: 179-180.5°C

MASS: 379 (MH⁺)

¹H-NMR (400 MHz, DMSO-d₆) δ: 3.82(3H, s), 4.70(2H, d, J=5.6Hz), 7.10(1H, d, J=8.4Hz), 7.35(1H, d, J=8.8Hz), 7.47(1H, d, J=2.0Hz), 8.63(1H, t, J=5.6Hz), 8.65(1H, d, J=8.8Hz), 8.71(1H, d, J=2.4Hz), 8.75(1H, dd, J=8.8, 2.4Hz)

50


55

Example 51

4-(3-Chloro-4-methoxybenzyl)amino-1-(4-hydroxypiperidino)-6-nitrophthalazine hydrochloride

5

10



15

20

In a similar manner to that of Example 4, the title compound was prepared from the compound prepared in Example 49.

M.p.: 245-246 (dec.) °C

25 MASS: 444 (MH⁺)

¹H-NMR (400 MHz, DMSO-d₆) δ: 1.70(2H, m), 1.96(2H, m), 3.05(2H, m), 3.48(2H, m), 3.77(1H, m), 3.86(3H, s), 4.78(2H, d, J=5.2Hz), 7.17(1H, d, J=8.4Hz), 7.48(1H, dd, J=8.4, 2.0Hz), 7.63(1H, d, J=2.0Hz), 8.34(1H, d, J=9.2Hz), 8.78(1H, dd, J=9.2, 2.0Hz), 9.78(1H, d, J=2.0Hz), 10.59(1H, br s), 14.04(1H, br s)


30 Example 52

4-(3-Chloro-4-methoxybenzyl)amino-1-[4-(hydroxymethyl)piperidino]-6-nitrophthalazine hydrochloride

35

40

45



50

In a similar manner to that of Example 4, the title compound was prepared from the compound prepared in Example 49.

M.p.: 232-233 (dec.) °C

MASS: 458 (MH⁺)


55 ¹H-NMR (400 MHz, DMSO-d₆) δ: 1.48(2H, m), 1.64(1H, m), 1.83(2H, m), 2.90(2H, m), 3.37(2H, d, J=6.4Hz), 3.61(2H, m), 3.85(3H, s), 4.77(2H, d, J=6.0Hz), 7.17(1H, d, J=8.4Hz), 7.48(1H, dd, J=8.4, 2.4Hz), 7.63(1H, d, J=2.4Hz), 8.32(1H, d, J=9.2Hz), 8.78(1H, dd, J=9.2, 2.0Hz), 9.77(1H, d, J=2.0Hz), 10.56(1H, br s)

Example 53

4-(3-Chloro-4-methoxybenzyl)amino-1-[4-(2-hydroxyethyl)piperidino]-6-nitrophthalazine hydrochloride

5

10



15

20

In a similar manner to that of Example 4, the title compound was prepared from the compound prepared in Example 49.

M.p.: 233-236 (dec.) °C

25 MASS: 472 (MH⁺)

1H-NMR (400 MHz, DMSO-d6) δ: 1.42-1.53(4H, m), 1.66(1H, m), 1.84(2H, m), 2.89(2H, m), 3.51(2H, t, J=6.6Hz), 3.58(2H, m), 3.85(3H, s), 4.76(2H, d, J=5.6Hz), 7.17(1H, d, J=8.8Hz), 7.47(1H, dd, J=8.8, 2.0Hz), 7.62(1H, d, J=2.0Hz), 8.33(1H, d, J=8.8Hz), 8.77(1H, dd, J=8.8, 2.0Hz), 9.74(1H, d, J=2.0Hz), 10.45(1H, br s)

30 Example 54

4-(3-Chloro-4-methoxybenzyl)amino-1-[4-(2-hydroxyethyl)piperazin-1-yl]-6-nitrophthalazine

35

40

45

50

In a similar manner to that of Example 3, the title compound was prepared from the compound prepared in Example 49.

M.p.: 199-200 (dec.) °C

MASS: 473 (MH⁺)


55 1H-NMR (400 MHz, CDCl₃) δ: 2.69(2H, t, J=5.4Hz), 2.80(4H, br s), 3.37(4H, br t), 3.70(2H, t, J=5.4Hz), 3.90(3H, s), 4.79(2H, d, J=5.2Hz), 6.87(1H, t, J=5.2Hz), 6.91(1H, d, J=8.4Hz), 7.37(1H, dd, J=8.4, 2.4Hz), 7.50(1H, d, J=2.4Hz), 8.16(1H, d, J=9.2Hz), 8.51(1H, dd, J=9.2, 2.0Hz), 9.13(1H, d, J=2.0Hz)

Example 55

1-(4-Ethoxycarbonylpiperidino)-4-(3-chloro-4-methoxybenzyl)amino-6-nitrophthalazine

5

10



15

20

In a similar manner to that of Example 3, the title compound was prepared from the compound prepared in Example 49.

M.p.: 208.5-209.5°C

25 MASS: 500 (MH⁺)

¹H-NMR (400 MHz, CDCl₃) δ: 1.30(3H, t, J=7.0Hz), 2.01-2.15(4H, m), 2.53-2.59(1H, m), 3.04-3.11(2H, m), 3.56-3.64(2H, m), 3.92(3H, s), 4.20(2H, q, J=7.0Hz), 4.79(2H, d, J=5.5Hz), 5.23(1H, t, J=5.5Hz), 6.94(1H, d, J=8.5Hz), 7.35(1H, dd, J=8.5, 2.0Hz), 7.48(1H, d, J=2.0Hz), 8.20(1H, d, J=9.0Hz), 8.55(1H, dd, J=9.0, 2.0Hz), 8.65(1H, d, J=2.0Hz)

30


Example 56

1-(4-Carboxypiperidino)-4-(3-chloro-4-methoxybenzyl)amino-6-nitrophthalazine hydrochloride

35

40

45



50

1-(4-Carboxypiperidino)-4-(3-chloro-4-methoxybenzyl)amino-6-nitrophthalazine was prepared from the compound prepared in Example 55 in a similar manner to that of Example 43 and further converted into the title compound in the same manner as that employed in Example 4 for the formation of hydrochloride.

M.p.: 137-143 (dec.) °C

55 MASS: 472 (MH⁺)


¹H-NMR (400 MHz, DMSO-d₆) δ: 1.85-1.92(2H, m), 1.97-2.05(2H, m), 2.50-2.60(1H, m), 2.96-3.03(2H, m), 3.52-3.56(2H, m), 3.86(3H, s), 4.75(2H, d, J=4.5Hz), 7.18(1H, d, J=8.5Hz), 7.46(1H, m), 7.61(1H, d, J=2.0Hz), 8.36(1H, d, J=9.0Hz), 8.76(1H, dd, J=9.0, 2.0Hz), 9.70(1H, m)

Example 57

1-Chloro-4-(3,4-methylenedioxybenzyl)amino-6-nitrophthalazine

5

10



15

In a similar manner to that of Example 1, the title compound was prepared from 1,4-dichloro-6-nitrophthalazine prepared in Preparative Example 8.

M.p.: 186.5-188.0°C

20 MASS: 359 (MH⁺)


¹H-NMR (400 MHz, CDCl₃) δ: 4.80(2H, d, J=5.0Hz), 5.73(1H, t, J=5.0Hz), 5.95(2H, s), 6.78(1H, d, J=8.0Hz), 6.92(1H, dd, J=8.0, 2.0Hz), 6.94(1H, d, J=2.0Hz), 8.37(1H, d, J=9.0Hz), 8.64(1H, dd, J=9.0, 2.0Hz), 8.73(1H, d, J=2.0Hz)

25 Example 58

4-Chloro-1-(3,4-methylenedioxybenzyl)amino-6-nitrophthalazine

30

35



40

In a similar manner to that of Example 2, the title compound was prepared from 1,4-dichloro-6-nitrophthalazine prepared in Preparative Example 8.

M.p.: 240-242 (dec.) °C

MASS: 359 (MH⁺)

¹H-NMR (400 MHz, CDCl₃) δ: 4.78(2H, d, J=5.0Hz), 5.52(1H, t, J=5.0Hz), 5.96(2H, s), 6.78(1H, d, J=8.0Hz), 6.91(1H, dd, J=8.0, 1.5Hz), 6.93(1H, d, J=1.5Hz), 7.98(1H, d, J=9.0Hz), 8.59(1H, dd, J=9.0, 2.0Hz), 9.05(1H, d, J=2.0Hz)

50


55

Example 59

1-(4-Dimethylaminopiperidino)-4-(3,4-methylenedioxybenzyl)amino-6-nitrophthalazine

5

10



15

20

In a similar manner to that of Example 3, the title compound was prepared from 1-chloro-4-(3,4-methylenedioxybenzyl)amino-6-nitrophthalazine prepared in Example 57.

M.p.: 105.0-107.0 °C

25 MASS: 451 (MH⁺)

¹H-NMR (400 MHz, CDCl₃) δ: 1.79(2H, ddd, J=13.0, 13.0, 4.0Hz), 2.04(2H, d, J=13.0Hz), 2.31-2.40(1H, m), 2.38(6H, s), 3.03(2H, dt, J=13.5, 1.5Hz), 3.66(2H, d, J=13.5Hz), 4.77(2H, d, J=5.0Hz), 5.15(1H, t, J=5.0Hz), 5.98(2H, s), 6.82(1H, d, J=8.0Hz), 6.94(1H, dd, J=8.0, 1.5Hz), 6.97(1H, d, J=1.5Hz), 8.19(1H, d, J=9.0Hz), 8.54(1H, dd, J=9.0, 2.0Hz), 8.63(1H, d, J=2.0Hz)

30


Example 60

1-(Imidazol-1-yl)-4-(3,4-methylenedioxybenzyl)amino-6-nitrophthalazine

35

40

45



In a similar manner to that of Example 3, the title compound was prepared from 1-chloro-4-(3,4-methylenedioxybenzyl)amino-6-nitrophthalazine prepared in Example 57.

M.p.: 154.0-155.5°C

50 MASS: 391 (MH⁺)


¹H-NMR (400 MHz, CDCl₃) δ: 4.89(2H, d, J=5.5Hz), 5.97(2H, s), 6.05(1H, t, J=5.5Hz), 6.82(1H, d, J=8.0Hz), 6.96(1H, dd, J=8.0, 2.0Hz), 6.98(1H, d, J=2.0Hz), 7.35(1H, s), 7.44(1H, s), 7.99(1H, d, J=9.0Hz), 8.02(1H, s), 8.61(1H, dd, J=9.0, 2.0Hz), 8.85(1H, d, J=2.0Hz)

Example 61

1-(4-Ethoxycarbonylpiperidino)-4-(3,4-methylenedioxybenzyl)amino-6-nitrophthalazine

5

10



15

20

In a similar manner to that of Example 3, the title compound was prepared from the compound prepared in Example 57.

M.p.: 220-222°C

MASS: 480 (MH⁺)

25

¹H-NMR (400 MHz, CDCl₃) δ: 1.30(3H, t, J=7.0Hz), 1.99-2.16(4H, m), 2.52-2.60(1H, m), 3.03-3.11(2H, m), 3.57-3.63(2H, m), 4.20(2H, q, J=7.0Hz), 4.77(2H, d, J=5.0Hz), 5.17(1H, t, J=5.0Hz), 5.98(2H, s), 6.82(1H, d, J=8.0Hz), 6.94(1H, dd, J=8.0, 1.5Hz), 6.97(1H, d, J=1.5Hz), 8.20(1H, d, J=9.0Hz), 8.54(1H, dd, J=9.0, 2.0Hz), 8.64(1H, d, J=2.0Hz)


30 Example 62

Potassium salt of 1-(4-carboxypiperidino)-4-(3,4-methylenedioxybenzyl)amino-6-nitrophthalazine

35

40

45



50

Potassium hydroxide (0.5 g) was dissolved in 30 ml of 50% aqueous methanol, followed by the addition of 0.26 g of the compound prepared in Example 61. The obtained mixture was stirred at room temperature for 4 hours.

The solvent was distilled away in a vacuum and water was added to the residue to form a solution. This solution was neutralized with dilute hydrochloric acid to precipitate a solid. This solid was recovered by filtration and dissolved in an aqueous solution of potassium carbonate. The obtained solution was adsorbed on an octadecylsilanol column and eluted with water/methanol to conduct purification. The obtained solid was crystallized from ethanol/ethyl acetate to give 0.15 g of the title compound as a pale-yellow solid.

M.p.: 206-209°C (dec.)

¹H-NMR (400 MHz, DMSO-d₆) δ: 1.64-1.76(2H, m), 1.76-1.84(2H, m), 1.84-1.92(1H, m), 2.65-2.73(2H, m),

EP 0 722 936 A1


3.26-3.32(2H, m), 4.53(2H, d, J=5.5Hz), 5.90(1H, t, J=5.5Hz), 5.92(2H, s), 6.82(1H, d, J=8.0Hz), 6.85(1H, dd, J=8.0, 1.0Hz), 6.95(1H, d, J=1.0Hz), 7.04(1H, d, J=2.0Hz), 7.09(1H, dd, J=9.0, 2.0Hz), 7.64(1H, d, J=9.0Hz)

Example 63

5

6-Amino-1-(4-ethoxycarbonylpiperidino)-4-(3,4-methylenedioxybenzyl)aminophthalazine hydrochloride

10



15

20

25 The compound (0.70 g) prepared in Example 61 was suspended in 50 ml of ethanol, followed by the addition of 50 ml of 10% palladium/carbon. The obtained mixture was stirred in a hydrogen atmosphere of 1 atm overnight and filtered to remove the catalyst. The filtrate was concentrated in a vacuum and the residue was dissolved in ethyl acetate. An excess of a 4N solution of hydrochloric acid in ethyl acetate was added to the obtained solution to form a hydrochloride. The solvent was distilled away in a vacuum. The obtained residue was recrystallised from ethanol/diisopropyl ether
30 to give 0.54 g of the title compound as a white powder.

M.p.: 156.5-158.5°C

MASS: 450 (MH⁺)

35 ¹H-NMR (400 MHz, CD₃OD) δ: 1.28(3H, t, J=7.0Hz), 1.95-2.03(2H, m), 2.04-2.12(2H, m), 2.57-2.65(1H, m),
J=8.0, 2.0Hz), 6.92(1H, d, J=2.0Hz), 7.29(1H, br s), 7.31(1H, d, J=9.0Hz), 7.90(1H, d, J=9.0Hz)


Example 64

40

1-(3-Chloro-4-methoxybenzyl)amino-4,6,7-trichlorophthalazine

45

50



55 In a similar manner to that of Example 1, the title compound was prepared from 1,4,6,7-tetrachlorophthalazine.
M.p.: 208-209°C

MASS: 404 (MH⁺)


1H-NMR (400 MHz, CDCl₃) δ: 3.90(3H, s), 4.77(2H, d, J=5.0Hz), 5.29(1H, t, J=5.0Hz), 6.91(1H, d, J=8.0Hz),
7.32(1H, dd, J=8.0, 2.0Hz), 7.45(1H, d, J=2.0Hz), 7.89(1H, s), 8.28(1H, s)

Example 65

1-(3-Chloro-4-methoxybenzyl)amino-6,7-dichloro-4-(4-hydroxypiperidino)phthalazine hydrochloride

5

10



15

20

In a similar manner to that of Example 4, the title compound was prepared from the compound prepared in Example 64.

M.p.: 174.0-175.5°C

25 MASS: 467 (MH⁺)

¹H-NMR (400 MHz, DMSO-d₆) δ: 1.63-1.73(2H, m), 1.91-1.99(2H, m), 3.00-3.08(2H, m), 3.39-3.49(2H, m), 3.73-3.81(1H, m), 3.86(3H, s), 4.71(2H, d, J=6.0Hz), 7.14(1H, d, J=8.5Hz), 7.45(1H, dd, J=8.5, 2.0Hz), 7.59(1H, d, J=2.0Hz), 8.16(1H, s), 9.26(1H, s)


30 Example 66

1-(3-Chloro-4-methoxybenzyl)amino-6,7-dichloro-4-(4-ethoxycarbonylpiperidino)phthalazine

35

40

45



50

In a similar manner to that of Example 3, the title compound was prepared from the compound prepared in Example 64.


¹H-NMR (400 MHz, CDCl₃) δ: 1.29(3H, t, J=7.0Hz), 1.96-2.13(4H, m), 2.48-2.55(1H, m), 3.98-3.05(2H, m), 3.53-3.58(2H, m), 3.86(3H, s), 4.19(2H, q, J=7.0Hz), 4.71(2H, d, J=5.0Hz), 5.31(1H, t, J=5.0Hz), 6.84(1H, d, J=8.5Hz), 7.27(1H, dd, J=8.5, 2.0Hz), 7.40(1H, d, J=2.0Hz), 7.94(1H, s), 8.08(1H, s)

Example 67

1-(4-Carboxypiperidino)-4-(3-chloro-4-methoxybenzyl)amino-6,7-dichlorophthalazine

5

10



15

20

In a similar manner to that of Example 43, the title compound was prepared from the compound prepared in Example 66.

M.p.: 268-273 (dec.) °C

25 MASS: 495 (MH⁺)

1H-NMR (400 MHz, DMSO-d₆) δ: 1.80-1.90(2H, m), 1.93-2.00(2H, m), 2.40-2.50(1H, m), 3.84-3.91(2H, m), 3.30-3.45(2H, m), 3.82(3H, s), 4.62(2H, d, J=5.5Hz), 7.10(1H, d, J=8.5Hz), 7.34(1H, dd, J=8.5, 2.0Hz), 7.44(1H, d, J=2.0Hz), 7.85(1H, t, J=5.5Hz), 8.05(1H, s), 8.68(1H, s)


30 Example 68

6-Chloro-1-(3-chloro-4-methoxybenzyl)amino-4-(3-pyridylmethyl)phthalazine dihydrochloride

35

40

45



In a similar manner to that of Example 4, the title compound was prepared from the compound prepared in Preparative Example 11.

50 M.p.: 168.5-169.5°C

MASS: 425 (MH⁺)


1H-NMR (400 MHz, DMSO-d₆) δ: 3.83(3H, s), 4.77(2H, s), 4.79(2H, s), 7.13(1H, d, J=8.5Hz), 7.47(1H, dd, J=8.5, 2.0Hz), 7.62(1H, d, J=2.0Hz), 7.89(1H, dd, J=7.5, 5.5Hz), 8.26(1H, dd, J=9.0, 2.0Hz), 8.34(1H, d, J=7.5Hz), 8.51(1H, d, J=2.0Hz), 8.76(1H, d, J=5.5Hz), 8.87(1H, s), 9.12(1H, d, J=9.0Hz), 11.01(1H, br s)

Example 69

6-Chloro-4-(3-chloro-4-methoxybenzyl)amino-1-(3-pyridylmethyl)phthalazine dihydrochloride

5

10



15

20 In a similar manner to that of Example 4, the title compound was prepared from the compound prepared in Preparative Example 12.

M.p.: 170.0-171.0°C

MASS: 425 (MH⁺)

25 ¹H-NMR (400 MHz, DMSO-d₆) δ: 3.85(3H, s), 4.78(2H, d, J=6.0Hz), 4.81(2H, s), 7.13(1H, d, J=8.5Hz), 7.48(1H, dd, J=8.5, 2.0Hz), 7.62(1H, d, J=2.0Hz), 7.95(1H, dd, J=8.0, 6.0Hz), 8.25(1H, dd, J=8.5, 2.0Hz), 8.40-8.46(2H, m), 8.81(1H, d, J=6.0Hz), 8.93(1H, d, J=1.0Hz), 9.26-9.31(1H, m), 10.91(1H, br s)


Example 70

30 4-(4-Ethoxycarbonylpiperidino)-1-(3,4-methylenedioxybenzyl)aminopyrido[3,4-d]pyridazine

35

40

45



The title compound was prepared in a similar manner to that of Example 45.

50 M.p.: 135-136°C

MASS: 436 (MH⁺)


55 ¹H-NMR (400 MHz, CDCl₃) δ: 1.30(3H, t, J=7.0Hz), 2.00-2.16(4H, m), 2.52-2.59(1H, m), 3.07-3.14(2H, m), 3.69-3.71(2H, m), 4.19(2H, q, J=7.0Hz), 4.74(2H, d, J=5.0Hz), 5.00(1H, t, J=5.0Hz), 5.96(2H, s), 6.80(1H, d, J=8.0Hz), 6.91(1H, dd, J=8.0, 1.5Hz), 6.94(1H, d, J=1.5Hz), 7.48(1H, dd, J=5.5, 1.0Hz), 8.93(1H, d, J=5.5Hz), 9.42(1H, d, J=1.0Hz)

Example 71

1-(4-Ethoxycarbonylpiperidino)-4-(3,4-methylenedioxybenzyl)aminopyrido[3,4-d]pyridazine

5

10



15

20

The title compound was prepared in a similar manner to that of Example 46.

M.p.: 119-120.5°C

MASS: 436 (MH⁺)

25 ¹H-NMR (400 MHz, CDCl₃) δ: 1.30(3H, t, J=7.0Hz), 1.97-2.15(4H, m), 2.51-2.59(1H, m), 3.01-3.08(2H, m), 3.61-3.67(2H, m), 4.19(2H, q, J=7.0Hz), 4.78(2H, d, J=5.0Hz), 5.24(1H, t, J=5.0Hz), 5.97(2H, s), 6.81(1H, d, J=8.0Hz), 6.93(1H, dd, J=8.0, 1.5Hz), 6.97(1H, d, J=1.5Hz), 7.75(1H, dd, J=5.5, 1.0Hz), 8.93(1H, d, J=5.5Hz), 9.21(1H, d, J=1.0Hz)

Example 72


30

4-(4-Carboxypiperidino)-1-(3,4-methylenedioxybenzyl)aminopyrido[3,4-d]pyridazine

35

40

45



50 In a similar manner to that of Example 43, the title compound was prepared from the compound prepared in Example 70.

M.p.: 138-140°C

MASS: 408 (MH⁺)


55 ¹H-NMR (400 MHz, DMSO-d₆) δ: 1.82-1.93(2H, m), 1.94-2.20(2H, m), 2.45-2.52(1H, m), 2.89-2.98(2H, m), 3.46-3.55(2H, m), 4.62(2H, d, J=5.5Hz), 5.96(2H, s), 6.85(1H, d, J=8.0Hz), 6.87(1H, dd, J=8.0, 1.0Hz), 6.97(1H, d, J=1.0Hz), 7.88(1H, t, J=5.5Hz), 8.17(1H, d, J=5.5Hz), 8.96(1H, d, J=5.5Hz), 9.29(1H, s), 12.25(1H, br s)

Example 73

1-(4-Carboxypiperidino)-4-(3,4-methylenedioxybenzyl)aminopyrido[3,4-d]pyridazine

5

10



15

20

In a similar manner to that of Example 43, the title compound was prepared from the compound prepared in Example 71.

M.p.: 205-206°C

MASS: 408 (MH⁺)

25

¹H-NMR (400 MHz, DMSO-d₆) δ: 1.80-1.91(2H, m), 1.94-2.01(2H, m), 2.42-2.50(1H, m), 2.84-2.92(2H, m), 3.42-3.48(2H, m), 4.64(2H, d, J=5.5Hz), 5.97(2H, s), 6.85(1H, d, J=8.0Hz), 6.89(1H, dd, J=8.0, 1.5Hz), 6.99(1H, d, J=1.5Hz), 7.76(1H, d, J=5.5Hz), 8.05(1H, t, J=5.5Hz), 8.93(1H, d, J=5.5Hz), 9.67(1H, s)

30


Claims

35

1. A fused pyridazine compound represented by the general formula (I) or a pharmacologically acceptable salt thereof:

35

40




45

{wherein C represents a five- or six-membered ring which may contain a heteroatom;
n is an integer of 0 to 4;

50

R¹ represents halogen, optionally substituted lower alkyl, optionally substituted lower alkoxy, optionally substituted cycloalkyl, nitro, cyano, -NR²R³ (wherein R² and R³ represent each independently hydrogen, optionally substituted lower alkyl, acyl, optionally substituted arylalkyl or optionally substituted heteroarylalkyl, or alternatively R² and R³ together with the nitrogen atom to which they are bonded may form a ring which may be substituted), -O-R⁹ (wherein R⁹ represents hydrogen, optionally substituted lower alkyl, acyl, optionally substituted arylalkyl or optionally substituted heteroarylalkyl), -S-R¹⁰ (wherein R¹⁰ represents hydrogen, optionally substituted lower alkyl, acyl, optionally substituted arylalkyl or optionally substituted heteroarylalkyl),

55




(wherein R^{11} represents hydrogen, lower alkyl or amino; and m is an integer of 0 to 2), or optionally protected carboxyl, with the proviso that when n is 2 to 4, R^1 's represent each independently a substituent selected from among those described above;

A represents hydrogen, halogen, $-\text{NR}^4\text{R}^5$ (wherein R^4 and R^5 represent each independently hydrogen, optionally substituted lower alkyl, acyl, optionally substituted arylalkyl or optionally substituted heteroarylalkyl, or alternatively R^4 and R^5 together with the nitrogen atom to which they are bonded may form a ring which may be substituted), optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl or optionally substituted heteroarylalkyl;

X represents $-\text{NR}^6-$ (wherein R^6 represents hydrogen, optionally substituted lower alkyl, optionally substituted arylalkyl or optionally substituted heteroarylalkyl) or $-\text{N}=$;

Y represents $-\text{CO}-$ or $-\text{CB=}$ [wherein B represents hydrogen, halogen, $-\text{NR}^7\text{R}^8$ (wherein R^7 and R^8 represent each independently hydrogen, optionally substituted lower alkyl, acyl, optionally substituted arylalkyl or optionally substituted heteroarylalkyl, or alternatively R^7 and R^8 together with the nitrogen atom to which they are bonded may form a ring which may be substituted), $-\text{O}-\text{R}^{12}$ (wherein R^{12} represents hydrogen, optionally substituted lower alkyl, acyl, optionally substituted arylalkyl or optionally substituted heteroarylalkyl), $-\text{S}-\text{R}^{13}$ (wherein R^{13} represents hydrogen, optionally substituted lower alkyl, acyl, optionally substituted arylalkyl or optionally substituted heteroarylalkyl), optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl or optionally substituted heteroarylalkyl]; and the symbol ----- represents a double bond or a single bond, with the proviso that the cases wherein C represents a benzene ring and n is 0 are excepted.


2. A fused pyridazine compound represented by the general formula (II) or a pharmacologically acceptable salt thereof:



(wherein R^1 , A, n, X and Y are each as defined above; and the symbol ----- represents a double bond or a single bond).

40

3. A fused pyridazine compound represented by the general formula (III) or a pharmacologically acceptable salt thereof:




55

[wherein R^{1a} represents halogen, optionally substituted lower alkyl, optionally substituted lower alkoxy, optionally substituted cycloalkyl, nitro, cyano or $-\text{NR}^2\text{R}^3$ (wherein R^2 and R^3 represent each independently hydrogen, optionally substituted lower alkyl, acyl, optionally substituted arylalkyl or optionally substituted heteroarylalkyl, or alternatively R^2 and R^3 together with the nitrogen atom to which they are bonded may form a ring which may be

substituted);

R¹, A and B are each as defined above; and
n' is an integer of 1 to 3].


5 4. A fused pyridazine compound represented by the general formula (IV) or a pharmacologically acceptable salt thereof:



15

(wherein R¹, R⁶, R^{1a}, n', A and B are each as defined above).


20 5. A fused pyridazine compound represented by the general formula (V) or a pharmacologically acceptable salt thereof:



30

(wherein R^{1a} and B are each as defined above; and R¹², R¹³ and R¹⁴ represent each independently hydrogen, halogen, optionally substituted lower alkyl or optionally substituted lower alkoxy, or alternatively two of R¹², R¹³ and R¹⁴ which are bonded to the carbon atoms adjacent to each other may be united to form methylenedioxy or ethylenedioxy).

35 6. A fused pyridazine compound represented by the general formula (VI) or a pharmacologically acceptable salt thereof:



45

50 (wherein R^{1a} and R⁶ are each as defined above; and R¹², R¹³ and R¹⁴ represent each independently hydrogen, halogen, optionally substituted lower alkyl or optionally substituted lower alkoxy, or alternatively two of R¹², R¹³ and R¹⁴ which are bonded to the carbon atoms adjacent to each other may be united to form methylenedioxy or ethylenedioxy)

55 7. A preventive and therapeutic agent for diseases for which a cyclic GMP phosphodiesterase inhibiting action is efficacious which comprises a fused pyridazine compound or pharmacologically acceptable salt thereof as set forth in claim 1 as an active ingredient.

8. A preventive and therapeutic agent for diseases for which an antiplatelet action is efficacious which comprises a fused pyridazine compound or pharmacologically acceptable salt thereof as set forth in claim 1 as an active ingredient.
- 5 9. A cyclic GMP phosphodiesterase inhibitor which comprises a fused pyridazine compound or pharmacologically acceptable salt thereof as set forth in claim 1 as an active ingredient.
- 10 10. An antiplatelet agent comprising a fused pyridazine compound or pharmacologically acceptable salt thereof as set forth in claim 1 as an active ingredient.
11. A preventive and therapeutic agent for hypertension which comprises a fused pyridazine compound or pharmacologically acceptable salt thereof as set forth in claim 1 as an active ingredient.
- 15 12. A preventive and therapeutic agent for pulmonary hypertension which comprises a fused pyridazine compound or pharmacologically acceptable salt thereof as set forth in claim 1 as an active ingredient.
13. A preventive and therapeutic agent for angina pectoris which comprises a fused pyridazine compound or pharmacologically acceptable salt thereof as set forth in claim 1 as an active ingredient.

20

25

30

35

40

45

50

55

INTERNATIONAL SEARCH REPORT		International application No. PCT/JP95/01575
A. CLASSIFICATION OF SUBJECT MATTER Int. Cl ⁶ C07D237/30, C07D237/32, C07D237/34, A61K31/50 According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) Int. Cl ⁶ C07D237/30, C07D237/32, C07D237/34, A61K31/50		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CAS ONLINE		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JP, 6-135938, A (Mitsubishi Kasei Corp.), May 17, 1994 (17. 05. 94), Claim & EP, 534443, A	1 - 13
X	JP, 2-129180, A (Morishita Seiyaku K.K.), May 17, 1990 (17. 05. 90), Claim (Family: none)	1 - 13
X	WO, 94/20508, A (EISAI CO., LTD.), September 15, 1994 (15. 09. 94), p. 345-346 & AU, 9461564, A	1-3, 5
X	US, 3494921, A (The Dow Chemical Company), February 10, 1970 (10. 02. 70), Column of claim (Family: none)	1
X	KORMENDY, K. et al. "Pyridazines condensed with a hetero ring. II. Aminopyrido(3,4-d)pyridazines. I. Separation and structure determination of the isomeric monochloro compounds obtained by hydrolysis of	1
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed		
"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search October 24, 1995 (24. 10. 95)	Date of mailing of the international search report November 14, 1995 (14. 11. 95)	
Name and mailing address of the ISA/ Japanese Patent Office Facsimile No.	Authorized officer Telephone No.	

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP95/01575

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>1,4-dichloropyrido(3,4-d)pyridazine", Acta Chim. Hung., <u>112</u>(4), (1983), p. 487-499, Compounds 2 to 5, 11, 21 to 24</p> <p>LEE, K. C. et al. "Comparisons of the depressor, inotropic and renal effects of milrinone and CI-930 to different pure vasodilators and diuretics in conscious instrumented dogs", Drugs Exp. Clin. Res., <u>17</u>(7), (1991), p. 323-336</p>	1. - 13

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

THIS PAGE BLANK (USPTO)